Document:

exv10w58

 

Exhibit 10.58

Valeant Pharmaceuticals North America

One Enterprise

Aliso Viejo, CA 92656

December 19, 2007

InterMune, Inc.

3280 Bayshore Boulevard

Brisbane, California 94005

	Re:	 	Product Acquisition Agreement (the “Product Acquisition Agreement”) dated as of November 28,
2005 by and between InterMune, Inc. (“Seller”) and Valeant Pharmaceuticals North America
(“Buyer”) – Transition Trademark License

Ladies and Gentlemen,

In connection with the Product Acquisition Agreement, Buyer and Seller wish to amend the terms of
the transition trademark license granted pursuant to the terms of Section 8.4 thereof, effective as
of the date hereof. Capitalized terms used herein without definition shall have the meaning
ascribed to them in the Product Acquisition Agreement.

1. The term of the license set forth in Section 8.4(a) of the Product Acquisition Agreement
(“Transition Trademark License”) is hereby extended from the date that is twenty-four (24) months
after the Closing up to and through June 30, 2008; and

2. Pursuant to Section 8.4(d) of the Product Acquisition Agreement, Seller hereby consents to the
assignment by Buyer of the Transition Trademark License to a Third Party that acquires from Buyer
the entire Product Business previously acquired by Buyer from Seller provided that (a) with respect
to the Transition Trademark License such acquirer agrees in writing to abide by the provisions of
Section 8.4 of the Product Acquisition Agreement, (b) such acquirer may not further assign such
Transition Trademark License, and (c) the Transition Trademark License is used only in the
Territory to permit such acquirer to sell Inventory that exists in saleable form as of the date
that such acquirer acquires the Product Business and such use in connection with the sale of such
Inventory by acquirer complies with all applicable governmental and regulatory laws and
regulations. In no event shall any assignment of the Transition Trademark License to such acquirer
be deemed to relieve Buyer of its liabilities or obligations to Seller under the Product
Acquisition Agreement and Buyer acknowledges and agrees that it shall remain fully and
unconditionally obligated and responsible for the full and complete performance of all of its
obligations under the Product Acquisition Agreement, including but not limited to the Transition
Trademark License.

Except as expressly amended herein, all terms and conditions contained in the Product Acquisition
Agreement remain unchanged and the Product Acquisition Agreement shall continue and remain in full
force and effect.

 

 

If the agreements and understandings contained in this letter agreement are acceptable to Seller,
please indicate such approval by signing this letter in the space indicated below and return a
fully executed copy of this letter to Buyer.

Sincerely,

/s/ Richard K. Masterson, Jr.

Richard K. Masterson, Jr.

Sr. Vice President

Global Commercial Development

Accepted and Agreed

InterMune, Inc.

	 	 	 	 	 
	By:

	 	/s/ Daniel G. Welch
 

Daniel G. Welch
	 	 
	 

	 	President and Chief Executive Officerexv10w59

 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

EXHIBIT 10.59

EXECUTION COPY

ASSET PURCHASE AGREEMENT

by and among

INTERMUNE, INC.

(the “Buyer”),

MARNAC, INC.

(“Marnac”)

and

DR. SOLOMON B. MARGOLIN

(“Dr. Margolin” and, collectively with Marnac, the “Sellers”)

Dated as of November 19, 2007

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 	 	 
	Section	 	Page	 
	ARTICLE 1 DEFINITIONS	 	 	1	 
	 
	 	Section 1.1	 	Defined Terms	 	 	1	 
	 
	 	Section 1.2	 	Construction	 	 	8	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 2 THE TRANSACTION	 	 	9	 
	 
	 	Section 2.1	 	Transfer of Purchased Assets	 	 	9	 
	 
	 	Section 2.2	 	Excluded Assets	 	 	9	 
	 
	 	Section 2.3	 	Assumed Liabilities	 	 	10	 
	 
	 	Section 2.4	 	Excluded Liabilities	 	 	10	 
	 
	 	Section 2.5	 	Purchase Price	 	 	11	 
	 
	 	Section 2.6	 	Risk of Loss	 	 	12	 
	 
	 	Section 2.7	 	Allocation	 	 	12	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 3 CLOSING	 	 	13	 
	 
	 	Section 3.1	 	Closing	 	 	13	 
	 
	 	Section 3.2	 	Closing Deliveries by the Sellers	 	 	13	 
	 
	 	Section 3.3	 	Closing Deliveries and Payments by the Buyer	 	 	13	 
	 
	 	Section 3.4	 	Closing Deliveries by the Buyer and the Sellers	 	 	14	 
	 
	 	Section 3.5	 	Liabilities Related to Finders’ or Brokers’ Fees	 	 	14	 
	 
	 	Section 3.6	 	Further Actions	 	 	14	 
	 
	 	Section 3.7	 	Withholdings	 	 	14	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE SELLERS	 	 	14	 
	 
	 	Section 4.1	 	Organization and Authority	 	 	15	 
	 
	 	Section 4.2	 	Title to Purchased Assets	 	 	15	 
	 
	 	Section 4.3	 	Consents; No Violations	 	 	15	 
	 
	 	Section 4.4	 	Compliance with Laws and Litigation	 	 	15	 
	 
	 	Section 4.5	 	Contracts	 	 	16	 
	 
	 	Section 4.6	 	Tax Matters	 	 	16	 
	 
	 	Section 4.7	 	Intellectual Property	 	 	16	 
	 
	 	Section 4.8	 	Product Records	 	 	17	 
	 
	 	Section 4.9	 	Brokers, Finders, etc	 	 	17	 
	 
	 	Section 4.10	 	No Other Agreements to Sell the Purchased Assets	 	 	18	 
	 
	 	Section 4.11	 	Disclosure	 	 	18	 
	 
	 	Section 4.12	 	Inventory	 	 	18	 
	 
	 	Section 4.13	 	Regulatory Approvals	 	 	18	 
	 
	 	Section 4.14	 	Regulatory Compliance	 	 	19	 
	 
	 	Section 4.15	 	Disclaimer of Implied Warranty	 	 	20	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BUYER	 	 	20	 
	 
	 	Section 5.1	 	Organization and Authority	 	 	21	 
	 
	 	Section 5.2	 	Consents; No Violations	 	 	21	 
	 
	 	Section 5.3	 	Brokers, Finders, etc	 	 	21	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 6 CERTAIN OTHER COVENANTS	 	 	21	 
	 
	 	Section 6.1	 	Cooperation	 	 	21	 
	 
	 	Section 6.2	 	Billing and Invoices	 	 	23	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	 	 	 	 	 	 	 	 
	Section	 	Page	 
	 
	 	Section 6.3	 	Adverse Experience Reports	 	 	24	 
	 
	 	Section 6.4	 	Regulatory Matters	 	 	24	 
	 
	 	Section 6.5	 	Covenant Not To Compete	 	 	24	 
	 
	 	Section 6.6	 	Exclusive License; Right of First Refusal	 	 	25	 
	 
	 	Section 6.7	 	Tax Matters	 	 	26	 
	 
	 	Section 6.8	 	Notice to Third Parties	 	 	28	 
	 
	 	Section 6.9	 	Clinical Trials	 	 	28	 
	 
	 	Section 6.10	 	Compassionate Use Programs	 	 	28	 
	 
	 	Section 6.11	 	Patent Maintenance	 	 	28	 
	 
	 	Section 6.12	 	[ * ]	 	 	28	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 7 CONDITIONS TO CLOSING	 	 	29	 
	 
	 	Section 7.1	 	Conditions Precedent to Buyer’s Obligations	 	 	29	 
	 
	 	Section 7.2	 	Conditions Precedent to Sellers’ Obligations	 	 	30	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 8 INDEMNIFICATION	 	 	31	 
	 
	 	Section 8.1	 	Survival of Representations and Warranties	 	 	31	 
	 
	 	Section 8.2	 	Indemnification	 	 	31	 
	 
	 	Section 8.3	 	Right of Setoff	 	 	33	 
	 
	 	 	 	 	 	 	 	 
	ARTICLE 9 MISCELLANEOUS PROVISIONS	 	 	33	 
	 
	 	Section 9.1	 	Confidentiality and Publicity	 	 	33	 
	 
	 	Section 9.2	 	Notices	 	 	34	 
	 
	 	Section 9.3	 	Governing Law	 	 	35	 
	 
	 	Section 9.4	 	Representation By Counsel	 	 	35	 
	 
	 	Section 9.5	 	Expenses	 	 	35	 
	 
	 	Section 9.6	 	Entire Agreement	 	 	35	 
	 
	 	Section 9.7	 	Amendment; Waiver	 	 	35	 
	 
	 	Section 9.8	 	Severability	 	 	35	 
	 
	 	Section 9.9	 	Assignment	 	 	36	 
	 
	 	Section 9.10	 	Counterparts	 	 	36	 
	 
	 	Section 9.11	 	Waiver of Jury Trial	 	 	36	 
	 
	 	Section 9.12	 	Consent to Jurisdiction	 	 	36	 
	 
	 	Section 9.13	 	Attorney Fees	 	 	36	 
	 
	 	Section 9.14	 	Remedies Cumulative; Specific Performance	 	 	36	 
	 
	 	Section 9.15	 	Time is of Essence	 	 	37	 
	 
	 	Section 9.16	 	Executory Nature of the Duties Imposed by this Agreement	 	 	37	 
	 
	 	Section 9.17	 	Bankruptcy Rights	 	 	37	 
	 
	 	Section 9.18	 	Release	 	 	37	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

EXECUTION COPY

ASSET PURCHASE AGREEMENT

(Marnac Agreement)

     This ASSET PURCHASE AGREEMENT (as amended from time to time, the “Agreement”), dated
November 19, 2007, is made and entered into by and among InterMune, Inc., a Delaware corporation
(the “Buyer”), Marnac, Inc., a New Jersey corporation (“Marnac”), and Dr. Solomon
B. Margolin (“Dr. Margolin” and, collectively with Marnac, the “Sellers”). The
Buyer and the Sellers are sometimes collectively referred to herein as the “Parties” and
individually as a “Party.”

RECITALS

     WHEREAS, the Buyer, the Sellers, KDL, Inc. (“KDL Japan”), KDL GmbH and Dr. Shitotomo
Yamauchi (the Sellers, KDL Japan, KDL GmbH and Dr. Shitotomo Yamauchi are collectively referred to
herein as the “Licensors”) are parties to that certain License Agreement dated as of March
29, 2002, as amended (the “Existing License Agreement”), pursuant to which the Licensors
granted to the Buyer certain limited rights and licenses related to anti-fibrotic uses of
Pirfenidone on a worldwide basis (except for Japan, Taiwan and Korea);

     WHEREAS, Marnac and KDL Japan are parties to that certain License Agreement dated November 5,
1996 (the “Shionogi License Agreement”) with Shionogi & Co., Ltd. (“Shionogi”)
pursuant to which Marnac and KDL Japan have granted to Shionogi certain limited rights and licenses
related to anti-fibrotic uses of Pirfenidone within Japan, Taiwan and Korea; and

     WHEREAS, the Sellers desire to sell certain assets related to Pirfenidone to the Buyer, and
the Buyer desires to purchase such assets from the Sellers, on the terms and subject to conditions
set forth herein.

     NOW, THEREFORE, in consideration of the promises, representations, warranties, covenants and
agreements contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree
as follows:

ARTICLE 1

DEFINITIONS

     Section 1.1 Defined Terms. For the purposes of this Agreement, the following words
and phrases shall have the following meanings whether in the singular or the plural:

     “Action” shall mean any action, claim, suit, litigation, proceeding, labor dispute,
arbitral action, governmental audit, inquiry, criminal prosecution, examination, investigation or
unfair labor practice charge or complaint commenced, brought, conducted or heard at law or in
equity or before any Governmental Authority or any arbitrator or arbitral panel.

     “Affiliate” shall mean any company or entity controlled by, controlling or under
common control with a Party. As used in the definition of “Affiliate,” “control” means (a) that
Person owns, directly or indirectly, more than fifty percent (50%) of the voting stock of another
entity, or (b) that a Person has the actual ability to control and direct the management of the
entity, whether by contract or otherwise.

     “Agreement” shall have the meaning set forth in the first paragraph of this Agreement.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-1-

 

     “Allocation” shall have the meaning set forth in Section 2.7.

     “Ancillary Agreements” shall mean, collectively, the Bill of Sale, the Assignment and
Assumption Agreement and the IP Assignments.

     “Approval Notice and Report” shall have the meaning set forth in Section
6.6(c).

     “Assignment and Assumption Agreement” shall have the meaning set forth in Section
3.4(a).

     “Assumed Contracts” shall have the meaning set forth in the definition of Purchased
Assets.

     “Assumed Liabilities” shall have the meaning set forth in Section 2.3.

     “Bill of Sale” shall have the meaning set forth in Section 3.2(a).

     “Business Day” means a day, which is not a Saturday, a Sunday, or a statutory holiday
in the United States.

     “Buyer” shall have the meaning set forth in the first paragraph of this Agreement.

     “Buyer Disclosure Schedule” shall have the meaning set forth in the first paragraph of
Article 5.

     “Buyer Proprietary Information” shall have the meaning set forth in Section
9.1(b).

     “CAPACITY Trial” shall mean (i) the randomized, double-blind, placebo controlled,
Phase III, three-arm study of the safety and efficacy of Pirfenidone in patients with idiopathic
pulmonary fibrosis under protocol PIPF-004; and (ii) the randomized, double-blind, placebo
controlled, Phase III study of the safety and efficacy of Pirfenidone in patients with idiopathic
pulmonary fibrosis under protocol PIPF-006, in each case as designed by and initiated by the Buyer.

     “Claim” shall have the meaning set forth in Section 8.2(c).

     “Claim Notice” shall have the meaning set forth in Section 8.2(c).

     “Clinical Trials” shall have the meaning set forth in the definition of Purchased
Assets.

     “Closing” shall have the meaning set forth in Section 3.1.

     “Closing Date” shall have the meaning set forth in Section 3.1.

     “Closing Payment” shall have the meaning set forth in Section 2.5(a).

     “Code” means the United States Internal Revenue Code of 1986, as amended.

     “Compassionate Use Programs” shall have the meaning set forth in Section
2.3(c).

     “Competing Product” shall mean any product that contains Pirfenidone. Notwithstanding
the foregoing, Competing Product shall not include those products containing Pirfenidone that (i)
are designed, marketed, sold and used exclusively for [ * ] indications (excluding [ * ]) and (ii)
are covered by a pending or issued claim of U.S. Patent No. [ * ], PCT Application No. [ * ], [ * ]
or [ * ], or any patent applications, provisional patent applications or similar instruments
(including any and all

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-2-

 

substitutions, divisions, continuations, reissues, renewals, extensions,
reexaminations, patents of addition, supplementary protection certificates, inventors’
certificates, pediatric data package exclusivity extensions, or the like) as well as any foreign
equivalents thereof (including certificates of invention and any applications therefor). Competing
Product shall also exclude any product in Japan, Korea or Taiwan under license of the Shionogi
Assets.

     “Confidentiality Agreement” shall have the meaning set forth in Section 9.1.

     “Consents” shall have the meaning set forth in Section 4.3(a).

     “Contract” shall mean any agreement, contract, lease, purchase, under, consensual
obligation, promise, or undertaking, obligation or commitment (whether written or oral), to which
one or more of the Sellers are a party that is primarily related to the Product, the Product
Business, the Purchased Assets or the Assumed Liabilities, or which is necessary for the conduct of
the Product Business to the extent conducted by the Sellers.

     “Copyrights” shall have the meaning set forth in the definition of Purchased Assets.

     “Damages” shall have the meaning set forth in Section 8.2(a).

     “Data Safety Exchange Agreement” shall have the meaning set forth in Section
6.3.

     “Diligence Period” shall have the meaning set forth in Section 6.6(c).

     “Dr. Margolin” shall have the meaning set forth in the first paragraph of this
Agreement.

     “EMEA” means the European Medicines Evaluation Agency.

     “Encumbrance” shall mean claims, security interests, liens, pledges, charges, escrows,
options, proxies, rights of first refusal, preemptive rights, mortgages, hypothecations,
assessments, prior assignments, title retention agreements, conditional sales agreements,
indentures, deeds of trust, leases, levies or security agreements of any kind whatsoever imposed
upon the subject property or item.

     “Excluded Assets” notwithstanding any other provision of this Agreement, shall mean
all assets and properties of the Sellers other than the Purchased Assets, including U.S. Patent No.
[ * ]; PCT Application No. [ * ]; [ * ]; [ * ]; and the Shionogi Assets.

     “Excluded Liabilities” shall mean all Liabilities or obligations of the Sellers (other
than the Assumed Liabilities), including any obligation or Liability of the Sellers created as a
result of this Agreement and those items set forth on Schedule 2.4(a).

     “Existing License Agreement” shall have the meaning set forth in the first sentence of
the Recitals.

     “FDA” means the United States Food and Drug Administration.

     “Governmental Authority” shall mean any (a) nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state,
local, municipal, foreign or other government; or (c) governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency, commission,
instrumentality, board, bureau, official, ministry, organization, unit, body or entity and any
court or other tribunal).

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-3-

 

     “IND” shall mean an Investigational New Drug Application (as defined under the United
States Food, Drug and Cosmetic Act and applicable Regulations promulgated thereunder).

     “Indemnified Party” shall have the meaning set forth in Section 8.2(c).

     “Indemnifying Party” shall have the meaning set forth in Section 8.2(c).

     “Intellectual Property” shall mean Copyrights, Know-How, Trademarks, Patents, and all
other intellectual property or proprietary rights, in each case whether or not subject to statutory
registration or protection.

     “Interim Agreement” shall mean the Interim Agreement, dated October 3, 2007, by and
among the Sellers and the Buyer.

     “IP Assignments” shall have the meaning set forth in Section 3.2(b).

     “IRS” means the United States Internal Revenue Service.

     “KDL Japan” shall have the meaning set forth in the first sentence of the Recitals.

     “Know-How” shall mean all trade secrets, technology, discoveries and improvements,
know-how, proprietary rights, formulae, confidential and proprietary information, technical
information, techniques, inventions, designs, drawings, procedures, processes, models,
formulations, manuals and systems, whether or not patentable or copyrightable, including all
biological, chemical, biochemical, toxicological, pharmacological and metabolic material and
information and data relating thereto and formulation, clinical, analytical and stability
information and data which have actual or potential commercial value and are not available in the
public domain.

     “Knowledge of the Sellers” or “to the Sellers’ Knowledge” or any similar such
statement with respect to the Sellers shall mean the best actual knowledge of any executive officer
or director of Marnac, any key employee of Marnac directly involved in the management, operation or
research and development of the Purchased Assets, or Dr. Margolin.

     “Law” shall mean any constitution, law, statute, treaty, role, directive, requirement
or Regulation or Order of any Governmental Authority.

     “Liability” shall mean, collectively, any indebtedness, guaranty, endorsement,
commitment, claim, loss, damage, deficiency, cost, expense, obligation or responsibility, fixed or
unfixed, known or unknown, choate or inchoate, liquidated or unliquidated, secured or unsecured,
direct or indirect, matured or unmatured, or absolute, contingent or otherwise, including any
product liability.

     “Licensors” shall have the meaning set forth in the first sentence of the Recitals.

     “MAA Milestone Payment” shall have the meaning set forth in Section
2.5(c)(iii).

     “Marnac” shall have the meaning set forth in the first paragraph of this Agreement.

     “Material Adverse Effect” shall mean any change, event or occurrence that has, or has
had, or is reasonably likely to have, a material adverse effect upon (a) the business, financial
condition or results of operations of the Product Business or the Purchased Assets, or (b) the
ability of a Party to consummate the transactions contemplated by this Agreement, other than (i)
any change, effect, event or condition that

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-4-

 

arises from changes in general economic conditions or
conditions affecting the pharmaceutical industry generally, or (ii) such changes, events or
conditions resulting from the announcement of, or the consummation of, the transactions
contemplated hereby.

     “Milestone Payments” shall mean, collectively, the Phase III Milestone Payment, the
NDA Milestone Payment and the MAA Milestone Payment.

     “NDA Milestone Payment” shall have the meaning set forth in Section
2.5(c)(ii).

     “Non-Income Taxes” shall mean (i) any real property, personal property, ad valorem and
other similar Taxes and (ii) any sales, use, transaction, excise and other similar Taxes;
provided, however, that “Non-Income Taxes” shall not include (a) any Taxes that are
income Taxes or Taxes in the nature of income Taxes or (b) any Transfer Taxes.

     “Officer’s Certificate” shall have the meaning set forth in Section 3.2(d).

     “Order” shall mean any: (a) temporary, preliminary or permanent order, judgment,
injunction, edict, decree, ruling, pronouncement, proclamation, directive, determination, decision,
opinion, verdict, sentence, stipulation, subpoena, writ or award that is or has been issued, made,
entered, rendered or otherwise put into effect by or under the authority of any court,
administrative agency or other Governmental Authority; or (b) Contract with any Governmental
Authority that is or has been entered into in connection with any Action.

     “[ * ]” shall mean [ * ].

     “Other Party” shall have the meaning set forth in Section 6.7(e)(iii).

     “Party” or “Parties” shall have the meaning set forth in the first paragraph
of this Agreement.

     “Patents” shall have the meaning set forth in the definition of Purchased Assets.

     “Permitted Encumbrances” shall mean liens imposed by any Governmental Authority for
Taxes not yet due and payable.

     “Person” shall mean any natural person, corporation, unincorporated organization,
partnership, association, joint stock company, joint venture, limited liability company, trust or
entity or organization of any kind or Governmental Authority.

     “Phase III Milestone Payment” shall have the meaning set forth in Section
2.5(c)(i).

     “Pirfenidone” shall mean that certain substance whose chemical composition is
5-methyl-1-phenyl-2-(1H)-pyridone (CAS 53179-13-8).

     “Post-Closing Tax Period” shall mean any Tax Period beginning after the close of
business on the Closing Date and the portion of any Straddle Period beginning after the Closing
Date.

     “Pre-Closing Tax Period” shall mean any Tax Period ending on or before the close of
business on the Closing Date and the portion of any Straddle Period ending on the Closing Date.

     “Patent Transferor” shall have the meaning set forth in Section 6.6(a).

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-5-

 

     “Product” shall mean any pharmaceutical composition or preparation, in any dosage,
strength or size, containing Pirfenidone.

     “Product Business” shall mean the manufacturing, using, developing, promoting,
selling, offering to sell, or importing of Pirfenidone for sale to the extent currently being or
previously conducted by the Sellers.

     “Product Copyrights” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Data” shall have the meaning set forth in the definition of Purchased Assets.

     “Product Intellectual Property” shall have the meaning set forth in the definition of
Purchased Assets.

     “Product Inventory” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Know-How” shall mean all Know-How as owned, licensed, sublicensed or
otherwise controlled by any Seller and primarily related to Pirfenidone, including as developed in
connection with clinical trials.

     “Product Patents” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Records” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Trademarks” shall have the meaning set forth in the definition of Purchased
Assets.

     “Purchased Assets” shall mean, collectively: (i) the Contracts or portions of the
Contracts set forth on Schedule 1.1(a) (the “Assumed Contracts”); (ii) as primarily
related to Pirfenidone, all permits, licenses, certificates, approvals, Product Registrations,
waivers, exemptions, qualifications, consents or orders of, filings and authorizations issued by
any Governmental Authority to the Sellers or their Representatives (the “Regulatory
Approvals”); (iii) all toxicology, pre-clinical, clinical and manufacturing information and
data, including with respect to clinical trials, and all submissions and correspondence with or to
any Governmental Authority regarding the Product, including all validation data and documentation
supporting the process of manufacturing the Product, but only to the extent the foregoing may be in
the possession or control of any Seller (or any Affiliate of any Seller) (the “Product
Data”); (iv) all domestic and foreign copyrights, copyright registrations, copyright
applications, original works of authorship fixed in any tangible medium of expression, including
literary works (including all forms and types of computer software, including all source code,
object code, firmware, development tools, files, records and data, and all documentation related to
any of the foregoing), pictorial, and graphic works relating to the Product Data and Product
Records (“Copyrights”), except for any Copyrights to published scientific papers,
unpublished academic materials, and submitted but unpublished scientific papers of Marnac,
including those by Dr. Margolin and Dr. Shri Giri, or other Marnac employees, as owned, licensed,
sublicensed or otherwise controlled by any Seller and primarily related to Pirfenidone
(“Product Copyrights”); ownership of Product Know-How for all uses (except for the Sellers’
use of the Product Know-How exclusively for satisfying their obligations under the Shionogi License
Agreement); (vi) the United States patents, patent applications, provisional patent applications
and similar instruments (including any and all substitutions, divisions, continuations,
continuations-in-part, reissues, renewals, extensions, reexaminations, patents of addition,
supplementary protection certificates, inventors’ certificates, pediatric data package exclusivity
extensions, or the like) as well as any foreign equivalents of the foregoing (including
certificates of invention and any applications therefor) (“Patents”) as owned (in whole or
in part), licensed, sublicensed or otherwise controlled by any Seller and primarily related to

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-6-

 

Pirfenidone (“Product Patents”); (vii) all domestic and foreign trademarks, trademark
registrations, trademark applications, service marks, service mark registrations, service mark
applications, business marks, brand names, trade names, names, internet domains and URLs, and all
goodwill associated therewith (“Trademarks”) as owned, licensed, sublicensed or otherwise
controlled by any Seller and primarily related to Pirfenidone (“Product Trademarks” and,
collectively with Product Copyrights, Product Know-How and Product Patents, “Product
Intellectual Property”); (viii) all files, documents, instruments, papers, books and records
owned or controlled by any Seller, whether in electronic or tangible form, to the extent relating
to the Purchased Assets, including any research and development files, marketing materials (if
any), regulatory files, adverse event reports and files, clinical studies and all documentation
relating to the Product Intellectual Property, but excluding any such items to the extent that any
applicable Law prohibits their transfer (the “Product Records”); (ix) all of Sellers’
rights under the contracts set forth in Schedule 1.1(a) relating to (A) the Pirfenidone
Phase II Trial in Children & Young Adults with NF1 and Plexiform Neurofibromas, under IND # 60,584
(IRB# 1072.04) held by the Mayo Clinic, Rochester, Minnesota, and (B) the trials in adults with
Neurofibromas, under IND # 60,584 (IRB# 1835.99) held by Dr. Dusica Babovic, Mayo Clinic,
Rochester, Minnesota (collectively, the “Clinical Trials”); and (x) all inventory owned by
any Seller or any of their respective Affiliates of finished Product (in powder, capsule or any
other form) or works in progress or materials used in the manufacture of finished Product, whether
held at a location or facility of any Seller or any of their respective Affiliate (or of any Person
on behalf of any Seller or any of their respective Affiliates) or in transit to or from any Seller
or any of their respective Affiliates (or any such other Person) (the “Product Inventory”).
The Parties agree that “Purchased Assets” does not include any of the Excluded Assets.

     “Product Registrations” shall mean all applications, all Investigational New Drug
Applications (INDs) and their foreign equivalents, new drug applications, abbreviated new drug
applications, new drug submissions, and any comparable applications and submissions, together with
any and all supplements or modifications or amendments thereto, whether existing, pending,
withdrawn or in draft form, together with all correspondence to or from any Governmental Authority
with respect thereto, prepared and submitted to any Governmental Authority with respect to any
Product.

     “Purchase Price” shall have the meaning set forth in Section 2.5.

     “Recipient Party” shall have the meaning set forth in Section 6.7(e)(iii).

     “Regulations” shall mean any laws, statutes, ordinances, regulations, rules, notice
requirements, court decisions, agency guidelines, principles of Law and orders of any foreign,
federal, state or local Governmental Authority.

     “Regulatory Approvals” shall have the meaning set forth in the definition of Purchased
Assets.

     “Released Claims” shall have the meaning set forth in Section 9.18.

     “Representative” shall mean any officer, director, principal, attorney, accountant,
agent, employee or other representative of any Person.

     “Restricted Territory” means the entire world.

     “Right of First Refusal” shall have the meaning set forth in Section 6.6(d).

     “ROFR Notice” shall have the meaning set forth in Section 6.6(d).

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-7-

 

     “Schedules” shall refer to the schedules to this Agreement which are hereby
incorporated by reference into this Agreement.

     “SEC” means the Securities and Exchange Commission.

     “Sellers” shall have the meaning set forth in the first paragraph of this Agreement.

     “Sellers Disclosure Schedule” shall have the meaning set forth in the first paragraph
of Article 4.

     “Sellers Proprietary Information” shall have the meaning set forth in Section
9.1(c).

     “Shionogi” shall have the meaning set forth in the second sentence of the Recitals.

     “Shionogi Assets” shall mean (i) the Shionogi License Agreement, (ii) [ * ] and other
Japanese patents and patent applications disclosing and claiming certain [ * ], as well as any and
all divisions, re-issues, continuations, substitutes and extension in part or all of such patents
or patent applications which are [ * ].

     “Shionogi License Agreement” shall have the meaning set forth in the second sentence
of the Recitals.

     “[ * ]” shall have the meaning set forth in [ * ].

     “Straddle Period” shall mean any Tax Period beginning before and ending after the
Closing Date.

     “Survival Date” shall have the meaning set forth in Section 8.1(a).

     “Taxes” mean any federal, state, local, foreign or other tax, levy, impost, fee,
assessment or other government charge, including without limitation income, estimated income,
business, occupation, franchise, property, payroll, personal property, sales, transfer, use,
employment, commercial rent, occupancy, franchise or withholding taxes, and any premium, including
without limitation interest, penalties and additions in connection therewith.

     “Tax Period” shall mean any period prescribed by any Governmental Authority for which
a Tax Return is required to be filed or a Tax is required to be paid.

     “Tax Return” shall mean any return, declaration, report, claim for refund, or
information return or statement relating to Taxes, including any schedule or attachment thereto,
and including any amendment thereof.

     “Trademarks” shall have the meaning set forth in the definition of Purchased Assets.

     “Transition Period” shall have the meaning set forth in Section 6.1(c).

     “Transfer Taxes” shall mean all transfer, documentary, sales, use, stamp,
registration, value added and other such Taxes and fees (including any penalties and interest)
incurred in connection with this Agreement and the transactions contemplated hereby.

     “Treasury Regulations” shall mean the income tax regulations issued under the Code.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-8-

 

     Section 1.2 Construction.

     (a) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this
Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement,
and Article, Section, Schedule and Exhibit references are to this Agreement unless otherwise
specified. The meaning of defined terms shall be equally applicable to the singular and plural
forms of the defined terms. The terms “include” and “including” and variations thereof, are not
limiting but rather shall be deemed to be followed by the words “without limitation.”

     (b) References to agreements and other documents shall be deemed to include all subsequent
amendments and other modifications thereto.

     (c) References to statutes shall include all regulations promulgated thereunder and references
to statutes or regulations shall be construed as including all statutory and regulatory provisions
consolidating, amending or replacing the statute or regulation.

     (d) References to “license” or “licenses” shall include “sublicense” or “sublicenses,” as
applicable.

     (e) The captions, titles and headings of this Agreement are for convenience of reference only
and shall not affect the construction of this Agreement.

     (f) Whenever the context requires: the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall include the masculine
and feminine genders.

     (g) The Parties participated jointly in the negotiation and drafting of this Agreement and the
language used in this Agreement shall be deemed to be the language chosen by the Parties to express
their mutual intent. If an ambiguity or question of intent or interpretation arises, then this
Agreement will accordingly be construed as drafted jointly by the Parties to this Agreement, and no
presumption or burden of proof will arise favoring or disfavoring any Party to this Agreement by
virtue of the authorship of any of the provisions of this Agreement.

     (h) The Schedules and Exhibits to this Agreement are a material part hereof and shall be
treated as if fully incorporated into the body of this Agreement.

ARTICLE 2

THE TRANSACTION

     Section 2.1 Transfer of Purchased Assets. At the Closing, upon the terms and
subject to the conditions hereof and in reliance upon the representations, warranties and covenants
contained herein and in consideration of the Purchase Price paid to the Sellers by the Buyer, the
Sellers will sell, convey, transfer, assign and deliver to the Buyer, and the Buyer will purchase,
take delivery of and acquire from the Sellers, all of the Sellers’ right, title and interest in and
to the Purchased Assets, free and clear of any Encumbrances, except for Permitted Encumbrances.

     Section 2.2 Excluded Assets. The Parties acknowledge and agree that the Sellers
are not selling, conveying, transferring, delivering or assigning any rights whatsoever to the
Excluded Assets to the Buyer, and the Buyer is not purchasing, taking delivery of or acquiring any
rights whatsoever to the Excluded Assets from the Sellers.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-9-

 

     Section 2.3 Assumed Liabilities. As of the Closing Date or such other date
specifically set forth in this Section 2.3, the Buyer shall assume and agree to pay,
perform or otherwise discharge, in accordance with their respective terms and subject to the
respective conditions thereof, only the following Liabilities (collectively, the “Assumed
Liabilities”):

     (a) Any Liability arising after the Closing Date under any Assumed Contract (other than any
Liability arising under those contracts constituting a part of the Clinical Trials or Compassionate
Use Programs, or out of or relating to a breach of, or default under, such Assumed Contract which
occurred on or prior to the Closing Date);

     (b) Any Liability associated with conducting the Clinical Trials after such Clinical Trials
are transferred to the Buyer under Section 6.1(d) (other than any Liability arising out of
or relating to the conduct of the Clinical Trials on or prior to the transfer of the Clinical
Trials to the Buyer under Section 6.1(d));

     (c) Any Liability associated with the contracts set forth in Schedule 1.1(a) which
relates to the “compassionate use” programs for Pirfenidone under [ * ] (the “Compassionate Use
Programs”) after the date such Compassionate Use Programs are transferred to the Buyer under
Section 6.1(d) (other than any Liability arising out of or relating to the conduct of the
Compassionate Use Programs on or prior to the transfer of the Compassionate Use Programs to the
Buyer under Section 6.1(d)); and

     (d) Any other Liability specifically set forth on Schedule 2.3(d) hereto.

For the avoidance of doubt, nothing in this Section 2.3 is intended to, or shall be
interpreted to, limit or otherwise reduce the Liabilities of the Buyer as they may occur and/or
exist after the Closing Date solely by virtue of the Buyer’s ownership, marketing or use of the
Purchased Assets, but rather, this Section 2.3 is solely intended to identify and provide
for the assumption by the Buyer of those Liabilities of the Sellers that are specifically assumed
by the Buyer hereunder and which, but for such assumption, would remain Liabilities of the Sellers.

     Section 2.4 Excluded Liabilities. Notwithstanding any other provision of this
Agreement, except for the Assumed Liabilities expressly assumed in Section 2.3, the Buyer
shall not assume, or otherwise be responsible for, any Liabilities of any Seller or any of their
respective Affiliates, whether liquidated or unliquidated, or known or unknown, whether arising out
of occurrences prior to, at or after the Closing Date (“Excluded Liabilities”), which
Excluded Liabilities shall include:

     (a) any Liability of any Seller that arises out of or relates to any Excluded Assets (for the
avoidance of doubt, the Parties agree that any Liabilities of Marnac and KDL Japan under the
Shionogi License Agreement shall remain the Liabilities of Marnac and KDL Japan and are Excluded
Liabilities);

     (b) any Liability of any Seller under or with respect to any Contract (other than an Assumed
Contract pursuant to Section 2.3(a));

     (c) any Liability of any Seller arising out of or related to any Action asserted on or prior
to the Closing Date against any Seller, or against or in respect of any Purchased Asset or the
conduct of the Product Business, or the basis of which shall have arisen on or prior to the Closing
Date;

     (d) any Liability arising from any injury to or death of any Person or damage to or
destruction of any property, whether based on negligence, breach of warranty, strict liability,
enterprise liability or any other legal or equitable theory arising from defects in products
manufactured or services performed by or on behalf of any Seller or any other Person on or prior to
the Closing Date;

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-10-

 

     (e) any Liability of any Seller arising out of or relating to the ownership or operation of
the Purchased Assets and/or the Product Business prior to Closing, including any claims,
obligations, rebates or litigation arising out of or relating to events or conditions
occurring prior to Closing or Products sold by any Seller prior to Closing;

     (f) any Liability to the extent arising out of or as a result of the conduct of any business
of the Sellers and their respective Affiliates other than those liabilities expressly assumed
herein pursuant to Section 2.3;

     (g) any Liability arising out of or relating to any finder’s fee, brokerage fee, commission or
similar payment in connection with any Seller’s entry into this Agreement or the consummation of
the transactions contemplated hereby, including any of the Contracts listed on Section 4.9
of the Sellers Disclosure Schedule; and

     (h) any Liability of any Seller, or any member of any consolidated, affiliated, combined or
unitary group of which any Seller is or has been a member, for any Tax, and any Liability for Taxes
attributable to the Purchased Assets or the Product Business for any Pre-Closing Tax Period.

     Section 2.5 Purchase Price. In consideration for the sale, transfer, conveyance,
assignment and delivery of the Purchased Assets and the execution and delivery of this Agreement
and the Ancillary Agreements by the Sellers, upon the terms and subject to the conditions set forth
in this Agreement (collectively, the “Purchase Price”):

     (a) Closing Payment. The Buyer shall make an upfront payment to the Sellers of
$6,750,000 and assume the Assumed Liabilities pursuant to Section 2.3. The Parties agree
that $2,100,000 of this upfront payment has been previously paid by the Buyer to the Sellers.
Therefore, at the Closing, the Buyer shall (i) deliver (or cause to be delivered) to the Sellers
the remainder of the upfront payment in the form of a nonrefundable payment in the aggregate amount
of $4,650,000 in cash, payable by wire transfer in immediately available funds in the allocations
and to the accounts specified in Schedule 2.5 (the “Closing Payment”); and (ii)
assume the Assumed Liabilities pursuant to Section 2.3.

     (b) Deferred Payment. Subject to Article 8, within ten (10) Business Days of
the first anniversary of the Closing Date, the Buyer shall deliver (or cause to be delivered) to
the Sellers a payment in the aggregate amount of $2,500,000 in cash payable by wire transfer in
immediately available funds in the allocations and to the accounts specified in Schedule
2.5.

     (c) Milestone Payments. Subject to Article 8:

          (i) By [ * ], the Buyer shall notify the Sellers of its decision, in the Buyer’s sole and
absolute discretion, to file or not to file (A) a New Drug Application for Pirfenidone for an
indication of idiopathic pulmonary fibrosis with the FDA, or (B) a Marketing Authorization
Application for Pirfenidone for an indication of idiopathic pulmonary fibrosis with the EMEA. If
the Buyer decides to file a New Drug Application with the FDA and/or a Marketing Authorization
Application with the EMEA, then within ten (10) Business Days of such notification to the Sellers,
the Buyer shall deliver (or cause to be delivered) to the Sellers an aggregate amount of [ * ] in
cash, payable by wire transfer in immediately available funds in the allocations and to the
accounts specified in Schedule 2.5 (the “Phase III Milestone Payment”).

          (ii) Upon the Buyer’s receipt of New Drug Application approval for Pirfenidone for an
indication of idiopathic pulmonary fibrosis in the United States, the Buyer shall deliver (or cause
to be delivered) to the Sellers an aggregate amount of $[ * ] in cash within fifteen (15) Business
Days, payable

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-11-

 

by wire transfer in immediately available funds in the allocations and to the
accounts specified in Schedule 2.5 (the “NDA Milestone Payment”); provided,
however, that the parties hereby acknowledge and agree that in the event the Buyer
determines, in good faith, that the labeling received by the Buyer from the FDA with respect to the
use of Pirfenidone for an indication of idiopathic pulmonary fibrosis materially and negatively
impacts the potential commercial value of Pirfenidone for idiopathic pulmonary fibrosis in the
United States, then the Sellers agree to, in good faith, (A) discuss with the Buyer the extent to
which labeling has negatively impacted the commercial value of Pirfenidone for idiopathic pulmonary
fibrosis in the United States and (B) negotiate an appropriate downward adjustment to the NDA
Milestone Payment to reflect such decrease in commercial value.

          (iii) Upon the Buyer’s receipt of Marketing Authorization Application approval for Pirfenidone
for an indication of idiopathic pulmonary fibrosis in Europe, the Buyer shall deliver (or cause to
be delivered) to the Sellers an aggregate amount of $[ * ] in cash within fifteen (15) Business
Days, payable by wire transfer in immediately available funds in the allocations and to the
accounts specified in Schedule 2.5 (the “MAA Milestone Payment”); provided,
however, that the parties hereby acknowledge and agree that in the event the Buyer
determines, in good faith, that the labeling received by the Buyer from the EMEA with respect to
the use of Pirfenidone for an indication of idiopathic pulmonary fibrosis materially and negatively
impacts the potential commercial value of Pirfenidone for idiopathic pulmonary fibrosis in Europe,
then the Sellers agree to, in good faith, (A) discuss with the Buyer the extent to which labeling
has negatively impacted the commercial value of Pirfenidone for idiopathic pulmonary fibrosis in
Europe and (B) negotiate an appropriate downward adjustment to the MAA Milestone Payment to reflect
such decrease in commercial value.

Each of the payments constituting the Purchase Price shall be deemed material, and any failure to
make any payment of any portion of the Purchase Price, if and when due, may be treated by the
Sellers as a material failure of consideration.

     Section 2.6 Risk of Loss. Until the Closing, any loss of or damage to the
Purchased Assets from fire, flood, casualty or any other similar occurrence shall be the sole
responsibility of the Sellers. As of the Closing, title to the Purchased Assets shall be
transferred to the Buyer. After the Closing, the Buyer shall bear all risk of loss associated with
the Purchased Assets and shall be solely responsible for procuring adequate insurance to protect
the Purchased Assets against any such loss.

     Section 2.7 Allocation. As soon as practicable after the Closing, the Parties
shall agree on an allocation (the “Allocation”) of the Purchase Price (including
any Assumed Liabilities to the extent properly taken into account under the Code and the Treasury
Regulations promulgated thereunder) among the Purchased Assets and the Sellers’ covenants under
Section 6.5 in accordance with the requirements of Section 1060 of the Code and consistent
with the principles set forth in Schedule 2.7. The Parties agree to be bound by the
Allocation, and the Parties shall act in accordance with the Allocation in the preparation of
financial statements and the filing of all Tax Returns (including, without limitation, filing IRS
Form 8594 with their Tax Returns for the taxable year that includes the Closing Date), before any
Tax authority or in any judicial proceeding unless it
has the written consent of the other Party to this Agreement or unless specifically required
pursuant to a final determination within the meaning of Section 1313(a) of the Code. No later than
thirty (30) days prior to the filing of their respective Forms 8594 (and analogous state law
forms), each Party shall deliver to the other Party a copy of such form. The Parties shall
promptly advise each other of the existence of any Tax proceeding related to the Allocation. In
the event of an adjustment to the Purchase Price pursuant to Section 6.7(c), the Buyer
shall amend the Allocation to reflect such adjustment, subject to approval by the Sellers, such
approval not to be unreasonably withheld. The Buyer and the Sellers agree to treat as interest for
Tax purposes any portion of the Purchase Price that is properly treated as interest under Section
483 of the Code (or any similar provision applicable under state or local Law).

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-12-

 

ARTICLE 3

CLOSING

     Section 3.1 Closing. Subject to the satisfaction or waiver of the conditions set
forth in Sections 7.1 and 7.2, the closing of the transactions contemplated herein in
connection with the purchase and sale of the Purchased Assets (the “Closing”) shall be held
at 10:00 a.m., local time, on the second (2nd) Business Day following the satisfaction
or waiver of all conditions to the obligations of the Parties to consummate the transactions
contemplated hereby (other than conditions with respect to actions the respective Parties shall
take at the Closing) at the offices of Latham & Watkins LLP, 140 Scott Drive, Menlo Park,
California 94025, or such other time or place as the Parties hereto shall otherwise agree (the
“Closing Date”).

     Section 3.2 Closing Deliveries by the Sellers. At the Closing, the Sellers shall
(i) take all steps necessary to place the Buyer in actual possession and operating control of the
Purchased Assets and (ii) deliver to the Buyer the following items, duly executed by the Sellers as
applicable, all of which shall be in form and substance reasonably acceptable to the Buyer and in
full force and effect:

     (a) Bill of Sale. Bill of Sale covering all of the applicable Purchased Assets,
substantially in the form of Exhibit A (the “Bill of Sale”);

     (b) Intellectual Property Assignment. Any and all documents necessary to properly
record the assignment to the Buyer of all of the Sellers’ right, title and interest in and to the
Product Intellectual Property, substantially in the form of Exhibit B (the “IP
Assignments”);

     (c) Consents. Duly executed Consents of all third parties (including any Governmental
Authorities), if any, required by the Sellers to consummate the transactions contemplated by this
Agreement and the Ancillary Agreements, in form and substance reasonably satisfactory to the Buyer,
including those Consents listed in Schedule 4.3(a);

     (d) Officer’s Certificates. A certificate executed on behalf of the Sellers by Dr.
Margolin (both individually and in his capacity as President of Marnac), dated as of the Closing
Date, certifying that the conditions set forth in Section 7.1(a), Section 7.1(b)
and Section 7.1(d) have been satisfied in all respects (the “Officer’s
Certificate”);

     (e) Secretary’s Certificate. A certificate of the Secretary of Marnac certifying as
to:

          (i) The certificate of incorporation and bylaws of Marnac as in effect as of the Closing Date;

          (ii) resolutions of Marnac’s board of directors authorizing the execution, delivery and
performance of this Agreement and the Ancillary Agreements; and

          (iii) the incumbency of Marnac’s officers executing this Agreement and the Ancillary
Agreements; and

     (f) Certificate of Good Standing. A certificate from the Secretary of State of New
Jersey and other applicable Governmental Authorities of the State of New Jersey as to Marnac’s good
standing and payment of all applicable taxes, dated no earlier than ten (10) Business Days prior to
the Closing Date.

     Section 3.3 Closing Deliveries and Payments by the Buyer. The Buyer shall pay the
Closing Payment.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-13-

 

     Section 3.4 Closing Deliveries by the Buyer and the Sellers. At the Closing, the
Buyer and the Sellers shall deliver the following items to one another, duly executed and in full
force and effect:

     (a) Assignment and Assumption Agreement. Assignment and Assumption Agreement,
covering all of the Assumed Liabilities, substantially in the form of Exhibit C (the
“Assignment and Assumption Agreement”).

     (b) Other Documentation. Such other certificates, instruments or documents required
pursuant to the provisions of this Agreement or otherwise necessary or appropriate to transfer the
Purchased Assets and Assumed Liabilities in accordance with the terms hereof and consummate the
transactions contemplated by this Agreement and the Ancillary Agreements, and to vest in the Buyer
full and complete title to the Purchased Assets free and clear of any Encumbrances, except for
Permitted Encumbrances.

     Section 3.5 Liabilities Related to Finders’ or Brokers’ Fees. For the avoidance of
doubt, the Parties agree that (i) all Liabilities in respect of finder’s fees, brokerage fees or
commissions or similar payments arising out of or relating to the Purchased Assets in connection
with any Seller’s entry into this Agreement or the consummation of any of the transactions
contemplated hereby shall remain Excluded Liabilities pursuant to Section 2.4, and (ii) the
Buyer shall reserve all rights pursuant to Article 8 (including Section 8.2(a)(iii)).

     Section 3.6 Further Actions. From and after the Closing, each Seller shall
cooperate with the Buyer and the Buyer’s Affiliates and Representatives, and shall execute and
deliver such documents and take such other actions as the Buyer may reasonably request, for the
purpose of evidencing the transactions contemplated by this Agreement or the Ancillary Agreements
and putting the Buyer in possession and control of all of the Purchased Assets, including using
their reasonable best efforts to obtain all necessary Consents from other parties to the Assumed
Contracts. Each of the Sellers hereby irrevocably nominates, constitutes and appoints the Buyer as
the true and lawful attorney-in-fact
of each of the Sellers (with full power of substitution) effective as of the Closing Date, limited
to the purposes contemplated by this Agreement and the Ancillary Agreements, and hereby authorizes
the Buyer (in the name of and on behalf of each of the Sellers) to execute, deliver, acknowledge,
certify, file and record any document, to institute and prosecute any Action and to take any other
action (on or at any time after the Closing Date) that the Buyer may deem reasonably appropriate
for the purpose of (a) collecting, asserting, enforcing or perfecting any claim, right or interest
of any kind that is included in or relates to any of the Purchased Assets, (b) defending or
compromising any claim or Action relating to any of the Purchased Assets (subject to the provisions
of Section 8.2 in the case of a Claim for indemnification) or (c) otherwise carrying out or
facilitating any of the transactions contemplated by this Agreement or the Ancillary Agreements.
The power of attorney referred to in the preceding sentence is and shall be coupled with an
interest and shall be irrevocable, and shall survive the dissolution or insolvency of Marnac.

     Section 3.7 Withholdings. The Buyer shall be entitled to deduct and withhold from
any consideration payable or otherwise deliverable pursuant to this Agreement such amounts as may
be required to be deducted or withheld therefrom under any provision of federal, local or foreign
Tax law or under any applicable Law. To the extent such amounts are so deducted or withheld, such
amounts shall be treated for all purposes under this Agreement as having been paid to the Person to
whom such amounts would otherwise have been paid.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-14-

 

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF THE SELLERS

     Each Seller represents and warrants, jointly and severally, to the Buyer that the statements
contained in this Article 4 are true and correct as of the date of this Agreement and will be true
and correct as of the Closing Date as if made on such date, except as set forth in the disclosure
schedules delivered by the Sellers to the Buyer on the date of this Agreement (collectively, such
schedules being referred to herein as the “Sellers Disclosure Schedule”). The Sellers
Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered sections
contained in this Article 4 and the disclosure in any paragraph shall qualify other sections in
this Article 4 only to the extent that it is readily apparent from a reading of such disclosure
that it also qualifies or applies to such other sections.

     Section 4.1 Organization and Authority. Marnac is a corporation duly organized,
validly existing and in good standing under the laws of the State of New Jersey. Each Seller has
all requisite power and authority to execute and deliver this Agreement and the Ancillary
Agreements, to perform its respective obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby and, in the case of Marnac, has duly authorized the
execution, delivery and performance of this Agreement and the Ancillary Agreements and transactions
or documents contemplated hereby and thereby by all necessary corporate action. The Sellers have
all requisite power and authority necessary to own, lease and operate their respective assets, to
carry on the Product Business to the extent currently being conducted by them, and to perform their
respective obligations under all Contracts. This Agreement and the Ancillary Agreements, when
executed and delivered by the Sellers, constitute the valid and legally binding obligations of the
Sellers, enforceable against each of them in accordance with their respective terms, subject to
applicable bankruptcy, moratorium, reorganization, insolvency and similar laws of general
application relating to or
affecting the rights and remedies of creditors generally and to general equitable principles
(regardless of whether in equity or at law).

     Section 4.2 Title to Purchased Assets. The Sellers have good and marketable title
to the Purchased Assets free and clear of any Encumbrances, except for Permitted Encumbrances.
Upon the consummation of the transactions contemplated hereby, the Buyer will acquire good and
marketable title to the Purchased Assets free and clear of any Encumbrances, except for Permitted
Encumbrances. None of the Sellers has received any notice of any adverse claims of ownership to or
right to use the Purchased Assets, and to the Sellers’ Knowledge, no facts or circumstances exist
which would provide a reasonable basis for any such adverse claim of ownership or right to use any
of the Purchased Assets.

     Section 4.3 Consents; No Violations.

     (a) Except for all filings and other actions contemplated by this Agreement and the Ancillary
Agreements (including the necessary transfer of filings, notices and approvals required to transfer
the Regulatory Approvals from the Sellers to the Buyer), the execution, delivery and performance by
the Sellers of this Agreement and the Ancillary Agreements and the consummation by the Sellers of
the transactions contemplated hereby and thereby will not require any notice to, filing with, or
the consent, approval or authorization of, any Person or Governmental Authority
(“Consents”).

     (b) Neither the execution and delivery of this Agreement or the Ancillary Agreements nor the
consummation of the transactions contemplated hereby or thereby will (i) violate or result in a
breach or result in the acceleration or termination of, or the creation in any third party of the
right to accelerate, terminate, modify or cancel, any Contract primarily related to the Purchased
Assets and/or the Assumed Liabilities, (ii) conflict with, violate or result in a breach of any
provision of the certificate of incorporation or by-laws of Marnac, or (iii) conflict with or
violate in any material respect any applicable Law.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-15-

 

     Section 4.4 Compliance with Laws and Litigation.

     (a) With respect to the Product Business, the Purchased Assets and the Assumed Liabilities, to
the Knowledge of the Sellers, the Sellers are in material compliance with all applicable Laws.

     (b) There is no existing or pending or, to the Knowledge of the Sellers, threatened Action
with respect to the Product Business, the Purchased Assets or the Assumed Liabilities or with
respect to this Agreement or the transactions contemplated hereby. None of the Sellers is subject
to any Order of any Governmental Authority that would reasonably be expected to impair or delay its
ability to perform its obligations under, and consummate the transactions contemplated, by this
Agreement.

     Section 4.5 Contracts.

     (a) The Sellers have delivered to or made available to the Buyer accurate and complete copies
of all Contracts primarily related to the Purchased Assets and/or the Assumed Liabilities. All
such Contracts to which any Seller is a party are, as to such Seller (and, as to the other parties
thereto, to the Knowledge of the Sellers), legal, valid and binding agreements in full force and
effect and enforceable in accordance with its terms (subject to applicable bankruptcy, moratorium,
reorganization, insolvency and similar laws of general application relating to or affecting the
rights and remedies of creditors generally and to general equitable principles (regardless of
whether in equity or at law)).

     (b) None of the Sellers is in breach or default, and no event has occurred that with notice or
lapse of time would constitute a breach or default by any Seller permitting termination,
modification, or acceleration, under any Contract primarily related to the Purchased Assets and/or
Assumed Liabilities. To the Knowledge of the Sellers, no other party to any Contract is in
material breach or default under, or has repudiated any material provision of, any Contract
primarily related to the Purchased Assets and/or Assumed Liabilities.

     Section 4.6 Tax Matters. Each Seller has timely filed all Tax Returns required to
be filed, and has paid all Taxes due, with respect to the Purchased Assets and the Product
Business. There are no Encumbrances on any of the Purchased Assets for Taxes (except for current
Taxes not yet due and payable). There are no asserted, and the Sellers have no Knowledge of any
basis for the assertion of any, claims relating to Taxes which, if adversely determined, could
reasonably be expected to result in any such Encumbrance.

     Section 4.7 Intellectual Property.

     (a) Section 4.7(a) of the Sellers Disclosure Schedule set forth a true and complete
list of the Product Patents and the Product Trademarks.

     (b) To the Knowledge of the Sellers, (i) the activities of the Sellers, if any, relating to
the development, manufacture, marketing, use, sale, distribution, import, export or other
commercial exploitation of Pirfenidone by the Sellers, in each case do not infringe upon,
misappropriate, violate, dilute (with respect to any trademarks, trade names, brand names and
service marks) or otherwise constitute the unauthorized use of, the Intellectual Property rights of
any third party; (ii) no claim is pending or, to the Knowledge of the Sellers, threatened against
the Sellers alleging any of the foregoing; and (iii) to the Knowledge of the Sellers, no right,
license, lease, consent or other agreement is required with respect to any Product Intellectual
Property for the conduct of the Product Business other than those included in the Purchased Assets.

     (c) To the Knowledge of the Sellers, none of the Product Patents is involved in any
litigation, reissue, interference, reexamination, or opposition, and there has been no threat or
other indication that any such proceeding will hereafter be commenced. To the Knowledge of the
Sellers, the Product Patents

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-16-

 

(excluding patent applications) (i) are in good standing, (ii) are all
without challenge of any kind, (iii) are valid and enforceable, and (iv) have not been adjudged
invalid or unenforceable in whole or in part.

     (d) To the Knowledge of the Sellers, none of the Product Trademarks or Product Copyrights is
involved in any cancellation, nullification, interference, conflict, concurrent use or
opposition proceeding, and there has been no threat or other indication that any such
proceeding will hereafter be commenced.

     (e) No Actions are pending, or to the Knowledge of the Sellers are threatened, against any of
the Sellers (i) based upon challenging or seeking to deny or restrict the use of any of the Product
Intellectual Property, or (ii) alleging that any services provided by, processes used by, or
products manufactured or sold by the Sellers in relation to the Product Business infringe or
misappropriate any Intellectual Property right of any third party.

     (f) To the Knowledge of the Sellers, all maintenance fees, annuity fees or renewal fee payment
for each jurisdiction in which each patent, patent application, trademark, trademark application,
trade name, trade name registration, brand name, brand name registration, service mark, service
mark registration, copyright, copyright application, domain name or domain name application
included within the Product Intellectual Property has issued or is pending have been timely paid.

     (g) To the Knowledge of the Sellers, no third party is engaging in any activity that infringes
or misappropriates the Product Intellectual Property. None of the Sellers is a party to any
agreement granting rights by the Sellers to any third party with respect to the Product
Intellectual Property.

     (h) The Sellers have, with respect to the Product Business, used commercially reasonable
efforts to maintain their trade secrets in confidence.

     (i) To the Knowledge of the Sellers, there has been no misappropriation of any trade secrets
or other confidential information of the Sellers with respect to the Product Business.

     (j) All employees of, consultants to or vendors of the Sellers with access to confidential
information with respect to the Product Business are parties to written agreements under which each
such employee, consultant or vendor is obligated to maintain the confidentiality of confidential
information of the Sellers. To the Knowledge of the Sellers, none of the employees, consultants or
vendors of the Sellers or any of their subsidiaries is in violation of such agreements.

     (k) The execution, delivery and performance of this Agreement, and the consummation of the
transactions contemplated hereby, will not result in or give rise to any right of termination or
other right to impair or limit, or otherwise result in a breach of, any of the Sellers’ rights to
own or retain a license to any of the Product Intellectual Property.

     (l) To the Knowledge of the Sellers, the Sellers have disclosed to the Buyer all patentable
Product Know-How.

     Section 4.8 Product Records. To the Knowledge of the Sellers, all of the Product
Records have been made available by the Sellers to the Buyer for examination, are complete and
correct in all material respects, and have been maintained in accordance with sound business
practices and applicable Law.

     Section 4.9 Brokers, Finders, etc. Except as set forth in Section 4.9 of the Sellers Disclosure Schedule, none of the
Sellers nor any of their respective officers, directors, employees,

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-17-

 

stockholders or Affiliates has
employed or made any agreement with any broker, finder or similar agent or any Person which will
result in the obligation of the Buyer or any of its Affiliates to pay any finder’s fee, brokerage
fees or commission or similar payment in connection with the transactions contemplated hereby.

     Section 4.10 No Other Agreements to Sell the Purchased Assets. None of the Sellers
nor any of Marnac’s officers, directors, stockholders or Affiliates has any commitment or legal
obligation, absolute or contingent, to any other Person other than the Buyer to sell, assign,
transfer or effect a sale of any of the Purchased Assets, to sell or effect a sale of a majority of
the capital stock of Marnac, to effect any merger, consolidation, liquidation, dissolution or other
reorganization of Marnac, or to enter into any agreement or cause the entering into of an agreement
with respect to any of the foregoing.

     Section 4.11 Disclosure. This Agreement, the Sellers Disclosure Schedule and the
Ancillary Agreements do not contain any untrue statement of a material fact or, to the Knowledge of
the Sellers, omit to state a material fact necessary in order to make the statements contained
herein or therein not misleading. The Sellers have provided the Buyer with all information
requested by the Buyer in connection with this transaction and all information that the Sellers
considers necessary or appropriate to enable the Buyer to decide whether to purchase the Purchased
Assets and assume the Assumed Liabilities. To the Sellers’ Knowledge, there are no facts which
(individually or in the aggregate) materially affect the Purchased Assets and/or the Assumed
Liabilities that have not been set forth in the Agreement, the Sellers Disclosure Schedule and the
Ancillary Agreements.

     Section 4.12 Inventory. Section 4.12(a) of the Sellers Disclosure Schedule
lists (i) the lot numbers associated with the Product Inventory and (ii) the manufacturing,
warehousing, distribution and consignee locations where the Product Inventory is located. To the
Sellers’ Knowledge, the Product Inventory represents all raw materials, API and finished goods
directly related to the Product that is currently owned and on hand or in the control of the
Sellers, at any of their warehouses, blenders, toll manufacturers, suppliers, or other third
parties and which has not otherwise been destroyed by the Sellers.

     Section 4.13 Regulatory Approvals.

     (a) Section 4.13(a) of the Sellers Disclosure Schedule sets forth a complete and
correct list of all Regulatory Approvals, including all Product Registrations. The Sellers have
provided to the Buyer complete and correct copies of the Regulatory Approvals or the Buyer has had
access to such copies of the Regulatory Approvals. The Regulatory Approvals are in full force and
effect and have been duly and validly issued.

     (b) To the Knowledge of the Sellers, the Sellers have all Regulatory Approvals necessary for
or used to carry on the Product Business as being conducted by the Sellers as of the Closing Date
and which are required by applicable Law.

     (c) To the Knowledge of the Sellers, the Sellers are in compliance with all of the Regulatory
Approvals listed on Section 4.13(a) of the Sellers Disclosure Schedule. Since the time the
Sellers acquired its rights in the Product, none of the Sellers has received any notification,
written or oral, from any Person with respect to any alleged or possible violation with respect to
any such Regulatory Approvals, and to the Sellers’ Knowledge, there are no facts or circumstances
that would form a reasonable basis for any such violation.

     (d) The Sellers own the Product Registrations and no other party has any rights thereto. To
the Knowledge of the Sellers, no applications made or other materials submitted by the Sellers to
the FDA, the EMEA or a notified body with respect to the Product contained an untrue statement of
material fact

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-18-

 

when submitted, or omitted to state a material fact within the Sellers’ Knowledge
when submitted which was required to be stated therein or necessary in order to make the statements
contained therein, in light of the circumstances under which they were made, not misleading.

     (e) The Product Registration files of the Sellers have been maintained in accordance with
reasonable industry standards. The Sellers have in their possession or control, or have access to,
copies of all the material documentation filed in connection with filings made by any Seller for
regulatory approval or registration of the Product, including the complete regulatory chronology
for each Product Registration (if applicable), and have provided to the Buyer complete and correct
copies of the Product Registration files.

     (f) None of the Sellers has received any Paragraph IV Notification under U.S.C. 355(j)(2)(B)
relative to any patents listed in any Product Registration held by any Seller. In addition, none
of the Sellers has received any notice regarding, and otherwise has no Knowledge of, any plans by
any third party to file a product registration relative to any Product Registration held by any
Seller.

	 	 	Section 4.14 Regulatory Compliance.

     (a) To the Knowledge of the Sellers, Pirfenidone has been developed, labeled, stored, tested
and distributed in compliance with all applicable requirements under the Federal Food Drug and
Cosmetic Act 21 U.S.C. §§301 et. seq., its implementing regulations, and all similar applicable
Laws, including those relating to investigational use, premarket clearance and applications or
abbreviated applications to market a new product, except for noncompliance which, individually or
in the aggregate, has not had and would not reasonably be expected to have a Material Adverse
Effect.

     (b) All preclinical trials and clinical trials conducted by or, to the Knowledge of the
Sellers, on behalf of the Sellers with respect to Pirfenidone have been, and are being, conducted
in compliance with the applicable requirements of Good Laboratory Practice and Good Clinical
Practice requirements contained in 21 C.F.R. Part 58 and Part 312 and all applicable requirements
relating to protection of human subjects contained in 21 C.F.R. Parts 50, 54, and 56, and all
similar applicable Laws, except for noncompliance which, individually or in the aggregate, has not
had and would not reasonably be expected to have a Material Adverse Effect.

     (c) To the Knowledge of the Sellers, with respect to Pirfenidone (i) all manufacturing
operations conducted for the benefit of the Sellers have been and are being conducted in compliance
with the FDA’s current Good Manufacturing Practice regulations for
drug products, including 21 C.F.R. Parts 210 and 211, and all similar applicable Laws, except
for noncompliance which, individually or in the aggregate, has not had and would not reasonably be
expected to have, a Material Adverse Effect; and (ii) the Sellers are in compliance with all
registration and listing requirements set forth in 21 U.S.C. §360 and 21 C.F.R. Part 207, and all
similar applicable Laws, except for noncompliance which, individually or in the aggregate, has not
had and would not reasonably be expected to have a Material Adverse Effect.

     (d) The Sellers have not received any notice that the FDA or any other Governmental Authority
has commenced, or threatened to initiate, any action to withdraw approval or request the recall of
Pirfenidone, or commenced, or threatened to initiate, any action to enjoin or place restrictions on
the production of Pirfenidone.

     (e) To the Knowledge of the Sellers, there are no facts, circumstances or conditions that
would be sufficient to presently, or solely with the passage of time in the ordinary course of
business, provide a reasonable basis for a recall, suspension or discontinuance of Pirfenidone.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-19-

 

     (f) With respect to any new drug application, investigational new drug application or similar
state or foreign regulatory application with respect to Pirfenidone, the Sellers are, to the
Knowledge of the Sellers, in compliance with 21 U.S.C. §§355 or 21 C.F.R. Parts 312 or 314,
respectively (and all similar applicable Laws), and all terms and conditions of such licenses or
applications. As to Pirfenidone, the Sellers and their respective officers, employees or agents
have included in each applicable application, where required, the certification described in 21
U.S.C. § 335a(k)(l) and each such certification was true, complete and correct in all material
respects when made.

     (g) With respect to Pirfenidone or the Product Business, the Sellers have not committed any
act, made any statement or failed to make any statement that would reasonably be expected to
provide a basis for the FDA to invoke its policy with respect to “Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities” set forth in 56 Fed. Reg. 46191 (September 10,
1991) and any amendments thereto. Additionally, none of the Sellers or any of their respective
officers, key employees or agents have been convicted of any crime or engaged in any conduct that
has resulted, or would reasonably be expected to result, in debarment under 21 U.S.C. Section 335a
or any similar state law or regulation under 42 U.S.C. Section 1320a-7.

     (h) The Sellers have delivered or made available to the Buyer copies of all serious adverse
event (SAE) reports received by the Sellers with respect to Pirfenidone.

     (i) Section 4.14(i) of the Sellers Disclosure Schedule sets forth (A) a true and
correct list of all current clinical trials with respect to the Product and (B) details regarding
the Compassionate Use Programs, in each case as conducted by or on behalf of the Sellers as of the
Closing Date.

     (j) None of the Sellers has received any notice from any other Governmental Authority that
such Governmental Authority has commenced, threatened or intends to commence any action or
investigation with respect to the Product Business, and there are no facts, circumstances or
conditions that would be sufficient to presently, or solely with the passage of time in the
ordinary course of business, provide a reasonable basis for any such action or investigation.

     Section 4.15 Disclaimer of Implied Warranty. EACH OF THE SELLERS HEREBY DISCLAIMS ANY IMPLIED WARRANTY AS TO THE LEGAL EFFECT OF THE
PURCHASED ASSETS, THE FITNESS OF THE PURCHASED ASSETS FOR THEIR INTENDED PURPOSE, THE
MERCHANTABILITY OF THE PURCHASED ASSETS, AND ALL OTHER WARRANTIES WHICH MAY BE IMPLIED AT LAW. THE
PURCHASED ASSETS ARE SOLD “AS IS”, WITHOUT WARRANTY OTHER THAN WARRANTIES OF TITLE AND WARRANTIES
EXPRESSLY SET OUT IN THIS AGREEMENT. This disclaimer of warranty, however, shall not disclaim the
implied contractual covenant of good faith and fair dealing, which the Sellers hereby expressly
recognize as applicable to this Agreement; and any warranty which may not be disclaimed as a matter
of patent or any other Law. The Buyer acknowledges that it is not relying upon any statement,
representation or warranty not expressly contained in this Agreement or in the Seller Disclosure
Schedule. Notwithstanding the foregoing, each Seller hereby acknowledges that nothing set forth in
this Section 4.15 shall relieve the Sellers of any liability to the Buyer arising out of
any actual fraud or intentional misrepresentation of the Sellers or any of their respective
Representatives in connection with the transactions contemplated by this Agreement.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-20-

 

ARTICLE 5

REPRESENTATIONS AND WARRANTIES OF BUYER

     The Buyer represents and warrants to the Sellers that the statements contained in this Article
5 are true and correct as of the date of this Agreement and will be true and correct as of the
Closing Date as if made on such date, except as set forth in the disclosure schedules delivered by
the Buyer to the Sellers on the date of this Agreement (the “Buyer Disclosure Schedule”).
The Buyer Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered
sections contained in this Article 5 and the disclosure in any paragraph shall qualify other
sections in this Article 5 only to the extent that it is readily apparent from a reading of such
disclosure that it also qualifies or applies to such other sections.

     Section 5.1 Organization and Authority. The Buyer is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware. The Buyer has all
requisite power and authority to execute and deliver this Agreement and the Ancillary Agreements,
to perform its respective obligations hereunder and thereunder and to consummate the transactions
contemplated hereby and thereby, and has duly authorized the execution, delivery and performance of
this Agreement and the Ancillary Agreements and transactions or documents contemplated hereby and
thereby by all necessary corporate action. This Agreement and the Ancillary Agreements, when
executed and delivered by the Buyer, constitute the valid and legally binding obligations of the
Buyer, enforceable against it in accordance with their respective terms, subject to applicable
bankruptcy, moratorium, reorganization, insolvency and similar laws of general application relating
to or affecting the rights and remedies of creditors generally and to general equitable principles
(regardless of whether in equity or at law).

     Section 5.2 Consents; No Violations.

     (a) Except for all filings and other actions contemplated by this Agreement and the Ancillary
Agreements (including the necessary transfer of filings, notices and approvals required
to transfer the Regulatory Approvals from the Sellers to the Buyer), the execution, delivery
and performance by the Buyer of this Agreement and the Ancillary Agreements and the consummation by
the Buyer of the transactions contemplated hereby and thereby will not require any notice to,
filing with, or the consent, approval or authorization of, any Person or Governmental Authority.

     (b) Neither the execution and delivery of this Agreement or the Ancillary Agreements nor the
consummation of the transactions contemplated hereby or thereby will (i) violate or result in a
breach or result in the acceleration or termination of, or the creation in any third party of the
right to accelerate, terminate, modify or cancel, any indenture, contract, lease, sublease, loan
agreement, note or other obligation or liability to which the Buyer is a party or is bound, (ii)
conflict with, violate or result in a breach of any provision of the certificate of incorporation
or by-laws of the Buyer, or (iii) conflict with or violate in any material respect any applicable
Law.

     Section 5.3 Brokers, Finders, etc. Neither the Buyer nor any of its officers,
directors, employees, stockholders or Affiliates has employed or made any agreement with any
broker, finder or similar agent or any person or firm which will result in the obligation of the
Buyer or any of its Affiliates to pay any finder’s fee, brokerage fees or commission or similar
payment in connection with the transactions contemplated hereby.

ARTICLE 6

CERTAIN OTHER COVENANTS

     Section 6.1 Cooperation.

     (a) After the Closing Date, the Parties shall cooperate reasonably with each other in connection
with any reasonable actions required to be taken with respect to their respective obligations

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-21-

 

under this Agreement and the Ancillary Agreements, and shall (i) furnish upon
reasonable request to each other such further information, (ii) execute and deliver to each other
such other reasonable documents, and (iii) do such other acts, all as the other Party may
reasonably request for the purpose of carrying out the provisions of this Agreement (and the
Ancillary Agreements) and the transactions contemplated hereby and thereby.

     (b) The Sellers will promptly notify the Buyer, and the Buyer will notify the Sellers, as
applicable and in writing, of any event or fact which represents a material breach of any of their
respective representations, warranties, covenants or agreements hereunder.

     (c) Within ninety (90) days of the Closing Date, the Sellers shall deliver (or cause to be
delivered) to the Buyer any Purchased Assets not required to be delivered at Closing pursuant to
Section 3.2 or required to be delivered within one hundred and eighty (180) days of the
Closing Date (the “Transition Period”) pursuant to Section 6.1(d).

     (d) Prior to the end of the Transition Period, the Sellers shall deliver (or cause to be
delivered) to the Buyer the Regulatory Approvals, the Clinical Trials, the Compassionate Use
Programs, the Product Inventory and the Product Records and Product Data relating to the Regulatory
Approvals, the Clinical Trials and the Product Inventory. Until such time as the Sellers have made
the deliveries specified in the preceding sentence, the Sellers shall continue to supply and
distribute, or cause one or more third parties to supply and distribute, Pirfenidone in the same
manner as Pirfenidone is currently being supplied and distributed by the Sellers, shall maintain
their systems as necessary in order to timely process and record the supply and distribution of
Pirfenidone as currently processed and recorded by the Sellers, and shall continue to comply in all
material respects with applicable Laws. The Parties acknowledge that this Section 6.1(d)
does not make any Seller an agent or legal representative of the Buyer for any purpose whatsoever,
and no Seller is granted any right or authority to assume or create any obligation or
responsibility, expressed or implied, on behalf of the Buyer, and that the Sellers, in fulfilling
their obligations under this Section 6.1(d), are independent contractors with respect to
the Buyer in all respects. The Parties further acknowledge that the Sellers will not receive any
consideration in addition to the Purchase Price for the performance of these services in this
Section 6.1.

     (e) From the Closing Date through the first anniversary of the Closing Date, upon the Buyer’s
request, each Seller shall: (i) reasonably assist the Buyer in the maintenance and renewal of any
Regulatory Approvals and the performance of any compliance activities under applicable Law, (ii)
reasonably assist the Buyer in the preparation of any maintenance or renewal filings with respect
to any Product Intellectual Property, and (iii) provide such other cooperation and assistance as
reasonably requested by the Buyer.

     (f) Notwithstanding anything to the contrary contained in this Agreement, if the sale,
assignment, transfer, conveyance or delivery or attempted sale, assignment, transfer, conveyance or
delivery to the Buyer of any asset that would be a Purchased Asset is (i) prohibited by any
applicable Law or (ii) would require any consents, waivers, approvals, authorizations of or notices
to a third Person or Governmental Authority and such consents, waivers, approvals, authorizations
or notices shall not have been obtained prior to the Closing, then in either case the Closing shall
proceed without the sale, assignment, transfer, conveyance or delivery of such asset and this
Agreement shall not constitute an agreement for the sale, assignment, transfer, conveyance or
delivery of such asset; provided that nothing in this Section 6.1(f) shall be
deemed to waive the rights of the Buyer not to consummate the transactions contemplated by this
Agreement if the conditions to the Buyer’s obligations set forth in Article 7 have not been
satisfied. In the event that the Closing proceeds without the sale, assignment, transfer,
conveyance or delivery of any such asset, then following the Closing, the Parties shall use their
commercially reasonable efforts, and cooperate with each other, to obtain promptly such consents,
waivers, approvals,

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-22-

 

authorizations or notices. Pending such consents, waivers, approvals,
authorizations or notices, the Parties shall cooperate with each other in any mutually agreeable,
reasonable and lawful arrangements designed to provide to the Buyer the benefits of use of such
asset and to the Sellers the benefits, including any indemnities, that, in each case, it would have
obtained had the asset been conveyed to the Buyer at the Closing. To the extent that Buyer is
provided the benefits pursuant to this Section 6.1(f) of any Contract, the Buyer shall (x)
perform for the benefit of the other parties thereto the obligations of any Seller or any Affiliate
of any Seller thereunder and (y) shall satisfy any related Liabilities with respect to such
Contract that, but for the lack of an authorization, approval, consent or waiver to assign such
obligations or Liabilities to the Buyer, would be Assumed Liabilities. Once consent, waiver,
approval, authorization or notice for the sale, assignment, transfer, conveyance or delivery of any
such asset not sold, assigned, transferred, conveyed or delivered at the Closing is obtained or
given, the Sellers shall assign, transfer, convey and deliver such asset to the Buyer at no
additional cost to the Buyer.

     (g) At least thirty (30) days prior to the submission for publication, including public
presentation, of any Copyrights primarily related to Pirfenidone, including any scientific papers
and academic materials by Dr. Margolin, Dr. Shri Giri, or other Marnac employees, the Sellers shall
provide complete copies of all such materials to the Buyer for the Buyer’s review. If the
materials provided to the Buyer are in draft form or are later revised prior to publication, the
Sellers shall continue to provide revised copies of all such materials until a complete and final
copy has been provided to the Buyer for the Buyer’s review. The Buyer will, in all such cases,
have at least thirty (30) days to review and comment on the materials prior to publication. The
Sellers shall reasonably consider for inclusion in such publication the comments of the Buyer.
Should the Buyer desire to file a patent application on any inventions within such proposed
publication, the Buyer shall so notify the Sellers prior to the expiration of the thirty (30) day
review period and the Sellers shall, upon receipt of such notice, delay publication for up to an
additional thirty (30) days and cooperate with the Buyer in the preparation of such patent
application; provided that this additional thirty-day (30-day) delay shall not apply to the
following studies:

	 	•	 	Pharmacokinetics and Metabolism of Intervenous Pirfenidone in Sheep (in press);
	 
	 	•	 	[ * ];
	 
	 	•	 	[ * ];
	 
	 	•	 	[ * ]; and
	 
	 	•	 	[ * ]

The Buyer shall own all rights, title and interest in all such patent applications and patents
claiming inventions disclosed in all such publications and materials. The Sellers hereby assign
all rights to any and all such patent applications and patents to the Buyer. The Sellers shall
cooperate with the Buyer to perfect any such assignments, including executing, or causing to be
executed, any formal papers necessary.

     Section 6.2 Billing and Invoices. In the event that any Seller or any of their
respective Affiliates receive payment after the Closing Date on invoices relating to any business
arising from the Purchased Assets operated by the Buyer or sales of products or services rendered
by the Buyer on or after the Closing Date, such Seller will promptly notify the Buyer of such
receipt and will promptly remit, or will cause such Affiliate to promptly remit, such
payment to the Buyer without depositing such payment in an account of such Seller, or such
Affiliate, unless in error, and such Seller, or such Affiliate, shall not be entitled to offset
such payment against any payments due such Sellers from the Buyer. In the event that any Seller
receives an invoice or request for payment relating to the operation of any business arising

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-23-

 

from the Purchased Assets on or after the Closing Date, or with respect to any Assumed Liability, such
Seller will promptly notify the Buyer of such request or invoice and forward the invoice and all
other appropriate information to the Buyer for payment. In the event the Buyer or any of its
Affiliates receive payment after the Closing Date on invoices issued by any Sellers relating to an
Excluded Asset or relating to product sold or services rendered by businesses other than those
relating to the Purchased Assets, the Buyer will promptly notify the Sellers of such receipt and
will promptly remit, or will cause such Affiliate to promptly remit, such payment to the Sellers
without depositing such payment in an account of the Buyer, or such Affiliate, unless in error, and
the Buyer, or such Affiliate, shall not be entitled to offset such payment against any payments due
the Buyer from the Sellers.

     Section 6.3 Adverse Experience Reports. Marnac and the Buyer hereby agree that the
obligations of the Parties under the Clinical Data Safety Exchange Agreement for Pirfenidone, dated
as of August 18, 2006 (the “Data Safety Exchange Agreement”), by and between the Buyer and
Marnac, shall continue in effect until, and terminate after, the earlier of (i) the end of the
Transition Period and (ii) the date that the last of the Regulatory Approvals to be transferred to
the Buyer have been transferred to the Buyer. After the Closing Date, the Buyer shall have all
responsibility for required reporting of adverse experiences for Pirfenidone.

     Section 6.4 Regulatory Matters.

     (a) Following the transfer of the Regulatory Approvals from the Sellers to the Buyer pursuant
to Section 6.1(d), the Buyer, at its cost, shall be solely responsible and liable for (i)
taking all actions, paying all fees and conducting all communication with the appropriate
Governmental Authority required by Law in respect of the Regulatory Approvals, including preparing
and filing all reports (including adverse drug experience reports) with the appropriate
Governmental Authority (whether Pirfenidone is sold before or after transfer of such Regulatory
Approval), (ii) taking all actions and conducting all communication with third parties in respect
of Pirfenidone sold pursuant to such Regulatory Approval (whether sold before or after transfer of
such Regulatory Approval), including responding to all complaints in respect thereof, including
complaints related to tampering or contamination, and (iii) investigating all complaints and
adverse drug experiences in respect of Pirfenidone sold pursuant to such Regulatory Approval
(whether sold before or after transfer of such Regulatory Approval).

     (b) The Sellers shall cooperate with the Buyer’s reasonable requests and use commercially
reasonable efforts to assist the Buyer in connection with the investigation of and response to any
complaint or adverse drug experience related to Pirfenidone.

     (c) The Sellers shall, within fifteen (15) Business Days following the transfer of the
Regulatory Approvals from the Sellers to the Buyer pursuant to Section 6.1(d), notify the
FDA and EMEA of the transfer of the Regulatory Approvals to the Buyer in accordance with all
applicable Laws.

     Section 6.5 Covenant Not To Compete.

     (a) Each Seller hereby agrees that for a period of ten (10) years from and after the Closing
Date, such Seller shall not, directly or indirectly, alone, as a licensor, or otherwise in
conjunction with any other Persons, through licenses or otherwise, develop, manufacture,
license-in, market, sell or otherwise distribute for human use, or assist any other Person, in
developing, manufacturing, licensing-in, marketing, selling or otherwise distributing for human
use, any Competing Product, either alone or in combination with another product, in all or any
portion of the Restricted Territory.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-24-

 

     (b) Acknowledgment of the Sellers. Each Seller hereby acknowledges that (i) the value
of the Purchased Assets is an integral component of the value of the transactions contemplated by
this Agreement to the Buyer, and (ii) the scope of the covenants contained in this Section
6.5, including as to time and geography, are necessary to preserve the value of the Purchased
Assets for the Buyer. Each Seller also acknowledges that the limitations of time, geography and
scope of activity agreed to in this Section 6.5 are ongoing executory duties of such Seller
and are reasonable because, among other things, (i) the Buyer and the Sellers are engaged in a
highly competitive industry, (ii) the Sellers have had unique access to the trade secrets and
know-how of the Purchased Assets, including the plans and strategy (and, in particular, the
competitive strategy) relating to the Purchased Assets, and (iii) the Sellers are receiving
significant consideration in connection with the consummation of the transactions contemplated by
this Agreement.

     (c) Non-Competition Covenants; Scope.

          (i) If any agreement in this Section 6.5 or any part of such agreement is held
invalid, void or unenforceable by any court of competent jurisdiction, such invalidity, voidness,
or unenforceability shall in no way render invalid, void, or unenforceable any other part of such
agreement or any separate agreement not declared invalid, void or unenforceable, and this
Section 6.5 shall in such case be construed as if the invalid, void, or unenforceable
provisions were omitted.

          (ii) If any court of competent jurisdiction shall determine that the provisions of this
Section 6.5 exceed the time, geographic or scope limitations permitted by applicable Law,
then such provisions shall nevertheless be enforceable by such court against any Seller upon such
shorter term, or within such lesser geographic area or scope, as may be determined by such court to
be reasonable and enforceable.

     (d) Injunctive Relief. The Parties agree that in the event of a breach by a Seller of
any of the covenants set forth in this Section 6.5, monetary damages alone would be
inadequate to fully protect the Buyer from, and compensate the Buyer for, the harm caused by such
breach or threatened breach. Accordingly, each Seller agrees that if it breaches or threatens
breach of any provision of this Section 6.5, the Buyer shall be entitled to, in addition to
any other right or remedy otherwise available, injunctive relief restraining such breach or
threatened breach and to specific performance of any such provision of this Section 6.5.
The Buyer shall not be required to post a bond or other security in connection with, or as a
condition to, obtaining such relief before a court of competent jurisdiction.

Section 6.6 Exclusive License; Right of First Refusal.

     (a) The Buyer hereby grants an irrevocable, fully paid-up, royalty-free, perpetual,
transferable, sublicensable, exclusive license to the Product Patents to the Seller or Sellers who
owned such Product Patent immediately prior to the consummation of the transactions contemplated by
this Agreement (the “Patent Transferor”) solely to the extent that such Product Patents [ *
] and solely to the extent necessary to [ * ]. The Buyer shall execute such documents to evidence
such transfers as may be
reasonably requested by the Sellers, including documents for filing with the United States
Patent and Trademark Office and other relevant patent agencies.

     (b) The Buyer shall have the right to terminate the license granted pursuant to Section
6.6(a) of this Agreement effective immediately upon written notice if any Patent Transferor or
any of their respective Affiliates, or any sublicensee under any patent right licensed to such
Patent Transferor under Section 6.6(a) of this Agreement or any of their respective
Affiliates challenges in a court of competent jurisdiction, the validity, scope or enforceability
of, or otherwise opposes, any patent right covered by the Product Patents, including any patent
right licensed to any Patent Transferor under Section 6.6(a) of this

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-25-

 

Agreement. If a sublicensee under any patent right licensed to such Patent Transferor under Section 6.6(a)
of this Agreement or any of their respective Affiliates challenges the validity, scope or
enforceability of or otherwise opposes any patent right covered by the Product Patents, including
any patent right licensed to any Patent Transferor under Section 6.6(a) of this Agreement
under which such sublicensee is sublicensed, then such Patent Transferor or its respective
Affiliate, as applicable, shall, upon written notice from the Buyer, terminate such sublicense.
Each Patent Transferor and its respective Affiliates shall include provisions in all agreements
under which a third party obtains a license under any patent right licensed to such Patent
Transferor under Section 6.6(a) of this Agreement providing that, if the sublicensee
challenges the validity or enforceability of or otherwise opposes any such patent right under which
the sublicensee is sublicensed, then such Patent Transferor may terminate such sublicense agreement
with such sublicensee, and such Patent Transferor shall, upon request by the Buyer, enforce such
right if such sublicensee breaches such restriction.

     (c) Each Patent Transferor agrees that for a period of six (6) years from the date of this
Agreement, such Patent Transferor shall not, directly or indirectly (including through any of its
Affiliates), at any time prior to the approval by the FDA of an IND or by the EMEA of a Clinical
Trial Authorization with respect to such [ * ], enter into any agreement, understanding or
arrangement (or discussions or negotiations therefor) with any Person that effects or contemplates
the licensing, sale or transfer of any rights in or to assets relating to such [ * ]. Upon the FDA
approval of an IND or the EMEA approval of a Clinical Trial Authorization with respect to such [ *
] at any time within the six (6) year period referenced in the foregoing sentence, such Patent
Transferor(s) shall promptly provide the Buyer with (i) a copy of such FDA or EMEA approval and
(ii) all the available and relevant data from the studies (collectively, the “Approval Notice
and Report”). The Buyer shall have the right to conduct due diligence for a period of up to
sixty (60) days from the date that Buyer receives the Approval Notice and Report from the Patent
Transferor(s) (such period, the “Diligence Period”). The Buyer’s due diligence during the
Diligence Period may include the following: (A) a full pre-clinical or clinical (as applicable) and
manufacturing audit of the Patent Transferor(s), (B) the right to reasonably request all relevant
data, including raw data, obtained to date, and (C) the right to inspect the Patent Transferor(s)
facilities and, to the extent within the reasonable control of the Patent Transferor(s), the
facilities of its clinicians and manufacturers (and the Patent Transferor(s) agree to use their
commercially reasonable efforts to ensure that the Buyer may inspect the facilities of such third
parties).

     (d) The Buyer shall have the right of first refusal (in its sole and absolute discretion) to
enter into negotiations with such Patent Transferor(s) for further research, development and
commercialization of an [ * ] in connection with an Approval Notice and Report (the “Right of
First Refusal”). The Buyer’s Right of First Refusal shall expire upon the expiration of the
underlying Diligence Period unless the Buyer exercises its Right of First Refusal by delivering
written notice to the Patent Transferor(s) (a “ROFR Notice”) prior to such expiration, in
which case the Parties shall negotiate in good faith to enter into a definitive agreement with
respect to the research, development and/or commercialization of such [ * ] within 90 days of the
Patent Transferor(s) receipt of such ROFR Notice. Each Patent Transferor further agrees to not,
directly or indirectly (including through any of its Affiliates), enter into any agreement,
understanding or arrangement (or discussions or negotiations therefor) with any Person (other
than the Buyer) that effects or contemplates the licensing, sale or transfer of any rights in
or to assets relating to such [ * ] unless and until the Buyer’s Right of First Refusal has expired
in accordance with this Section 6.6(d).

     Section 6.7 Tax Matters.

     (a) Notices. The Sellers shall promptly notify the Buyer in writing upon receipt by
the Sellers of notice of any pending or threatened Tax audits or assessments relating to the
income, properties or operations of the Sellers that reasonably may be expected to relate to the
Purchased Assets, the

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-26-

 

Assumed Liabilities or the Product Business. The Buyer shall promptly notify
the Sellers in writing upon receipt by the Buyer of notice of any pending or threatened Tax audits
or assessments relating to the Product Patents as to which the Sellers have an interest pursuant to
Section 6.6(a) or Section 6.9.

     (b) Transfer Taxes. All Transfer Taxes shall be paid by the Sellers when due, and the
Sellers shall, at their own expense, file all necessary Tax Returns and other documentation with
respect to all such Transfer Taxes and, if required by applicable Law, the Buyer shall join in the
execution of any such Tax Returns and other documentation. As soon as reasonably practicable
following the Closing, the Sellers shall provide the Buyer with (i) evidence satisfactory to the
Buyer that such Transfer Taxes have been paid by the Sellers and (ii) a clearance certificate or
similar document(s) which may be required by any state Tax authority to relieve the Buyer of any
obligation to withhold any portion of the payments to the Sellers pursuant to this Agreement.

     (c) Characterization of Payments. Except as otherwise provided in this Agreement, any
payments made pursuant to any indemnification obligation under this Agreement shall constitute an
adjustment of the consideration paid for the Purchased Assets for Tax purposes and shall be treated
as such by the Buyer and the Sellers on their Tax Returns to the extent permitted by Law.

     (d) FIRPTA Certificate. The Sellers shall deliver to the Buyer at the Closing a
certificate, duly executed and acknowledged, in form and substance satisfactory to the Buyer,
certifying such facts as would exempt the transactions contemplated hereby from withholding
pursuant to the provisions of the Foreign Investment in Real Property Tax Act.

     (e) Allocation of Taxes.

          (i) Except as otherwise provided in this Section 6.7, the Sellers shall be responsible
for, and shall timely pay, all Taxes levied with respect to the Purchased Assets and the Product
Business attributable to the Pre-Closing Tax Period.

          (ii) Non-Income Taxes for any Straddle Period shall be apportioned between the Pre-Closing Tax
Period and the Post-Closing Tax Period as follows: (A) in the case of personal property Taxes, real
property Taxes and any other Taxes other than sales, use, transaction or excise Taxes and other
similar Taxes, the portion allocable to the Pre-Closing Tax Period shall be deemed to be the amount
of such Tax for the entire Straddle Period multiplied by a fraction the numerator of which is the
number of days in the portion of the Straddle Period ending on the Closing Date and the denominator
of which is the number of days in the entire Straddle Period, and (B) in the case of any sales,
use, transaction or excise Taxes or other similar Taxes, the portion allocable to the Pre-Closing
Tax Period shall be deemed equal to the amount which would be payable if the relevant Straddle
Period ended on the Closing Date. The Sellers shall be liable for Non-Income Taxes apportioned to
the Pre-Closing Tax Period, and the Buyer shall be liable for Non-Income Taxes apportioned to the
Post-Closing Tax Period.

          (iii) Upon receipt by the Buyer, on the one hand, or a Seller, on the other, of any bill for
Taxes relating to the Purchased Assets or the Product Business, the Party receiving such bill (the
“Recipient Party”) promptly shall present a statement to the other Party (the “Other
Party”) setting forth the amount of such Taxes for which the Other Party is liable under this
Section 6.7(e), together with such supporting evidence as is reasonably necessary to
calculate the amount of such Taxes. The apportioned amount of Taxes for which the Other Party is
liable shall be paid by the Other Party to the Recipient Party within 15 days after delivery of
such statement to the Other Party by the Recipient Party. The Recipient Party shall be responsible
for the timely payment of the Taxes to which such bill relates. In the event that a Party shall
make any payment to any Taxing or other authority of any Taxes apportioned to the Other Party under
Section 6.7(e), the Other Party shall reimburse the paying Party for the amount of such
Taxes

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-27-

 

apportioned to the Other Party promptly but in no event later than 15 days after the
presentation by the paying Party of a statement setting forth the amount of reimbursement to which
the paying Party is entitled along with such supporting evidence as is reasonably necessary to
calculate the amount of such reimbursement. The portion of any refund of Taxes attributable to
amounts apportioned hereunder to and paid or reimbursed by the Party not receiving such refund
shall be the property of the Party not receiving such refund, and the Party receiving such refund
shall promptly pay to the Party not receiving such refund that portion of such refund so
attributable.

     (f) Cooperation. The Buyer and the Sellers agree to furnish or cause to be furnished
to the other, upon request, as promptly as practicable, such information and assistance relating to
the Purchased Assets or the Product Business as is reasonably necessary for the filing of Tax
Returns and the prosecution or defense of any audit, claim, suit or proceeding relating to any Tax.
The Parties shall retain all books and records with respect to Taxes pertaining to the Purchased
Assets for a period of at least seven (7) years following the Closing Date. At the end of such
period, the Parties shall provide the other Party with reasonable prior written notice before
disposing of such books and records and to allow the other Party to take possession, at its own
expense, of such books and records. The Parties shall cooperate fully with each other in the
conduct of any audit or other proceeding relating to Taxes pertaining to the Purchased Assets and
further agree to use their best efforts to obtain any certificate or other document from any
Governmental Authority or other Person as may be necessary to mitigate, reduce or eliminate any Tax
that could be imposed (including with respect to the transactions contemplated hereby).

     Section 6.8 Notice to Third Parties. The Sellers agree to cooperate with the
Buyer, at the Buyer’s reasonable request, in the notification to third parties of the transactions
contemplated by this Agreement and the Sellers agree not to notify any third parties of such
transactions without the consent of the Buyer.

     Section 6.9 Clinical Trials. Following the transfer of the Clinical Trials from
the Sellers to the Buyer pursuant to Section 6.1(d), the Buyer shall take over and assume
(a) all of the Sellers’ duties and responsibilities related to the ongoing conduct of the Clinical
Trials from and after such transfer in accordance with the protocols therefore and (b) the related
Liabilities described in Section 2.3(b).

     Section 6.10 Compassionate Use Programs. Following the transfer of the
Compassionate Use Programs from the Sellers to the Buyer pursuant to Section 6.1(d), the
Buyer shall take over and assume (a) all of the Sellers’ duties and responsibilities related to the
ongoing conduct of the Compassionate Use Programs from and after such transfer in accordance with
the protocols therefore and (b) the related Liabilities described in Section 2.3(c).

     Section 6.11 Patent Maintenance. After the Closing Date, the Buyer shall assume
the duty to make all required maintenance and prosecution payments as to the Product Patents for
the remaining terms thereof; provided, however, that upon ninety (90) days written notice, the
Buyer may transfer any of the Product Patents to the Patent Transferor from which the Buyer
purchased such Product Patent in lieu of making further maintenance or prosecution payments.
Nothing in this Section 6.11 shall obligate the Sellers to assume any further maintenance
or prosecution payments.

     Section 6.12 [ * ]. The Buyer shall have the right of first refusal to acquire the
[ * ] from the Sellers. The Sellers agree not to, directly or indirectly (including through any of
its Affiliates), enter into any agreement, understanding or arrangement with any Person [ * ] that
effects or contemplates the licensing, sale or transfer of any rights in or to the [ * ] without
first offering Buyer the opportunity to acquire such rights in or to the [ * ] on the same or
economically equivalent terms. If any Seller plans to transfer, assign or dispose of any of its
rights in or to the [ * ], such Seller shall notify the Buyer promptly, and the Buyer and the
Sellers shall promptly negotiate in good faith to enter into a definitive agreement with respect to
the sale of the [ * ] to the Buyer for [ * ] days (the “[ * ]”). In addition, if the Sellers
receive notification from [ * ] that it consents to the sale of the [ * ] to the Buyer, Sellers
agree to promptly notify the Buyer of such consent and the Buyer and the Sellers agree to promptly
negotiate in good faith to enter into a definitive agreement

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-28-

 

with respect to the sale of the [ * ].
After the expiration of the [ * ], if the Parties cannot agree on a definitive agreement, then the
Sellers may enter into negotiations with third parties with respect to the sale or transfer of the
[ * ]. Notwithstanding the foregoing, this Section 6.12 shall not prevent the Sellers from
entering into a non-binding term sheet with any Person for the licensing, sale or transfer of any
rights in or to the [ * ], provided that any transaction contemplated by such term sheet is
subject to the Buyer’s right of first refusal set forth in this Section 6.12.

ARTICLE 7

CONDITIONS TO CLOSING

     Section 7.1 Conditions Precedent to Buyer’s Obligations. Buyer’s obligations to
consummate the transactions contemplated by this Agreement and the Ancillary Agreements shall be
subject to the fulfillment of each of the following additional conditions, any one or more of which
may be waived, at Buyer’s sole discretion, in writing by the Buyer:

     (a) Representations and Warranties.

          (i) Each of the representations and warranties of the Sellers set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Buyer by the Sellers under
this Agreement (including the Officer’s Certificate) that is not qualified by “Material Adverse
Effect” or other materiality qualifications shall have been true and correct in all material
respects as of the date of this Agreement and shall be true and correct in all material respects as
of the Closing Date as if made at the Closing Date (except to the extent such representation or
warranty specifies an earlier date, in which case such representation or warranty shall be true and
correct in all material respects as of such date); and

          (ii) Each of the representations and warranties of the Sellers set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Buyer by the Sellers under
this Agreement (including the Officer’s Certificate) that is qualified by “Material Adverse Effect”
or other materiality qualifications shall have been true and correct in all respects as of the
date of this Agreement and shall be true and correct in all respects as of the Closing Date as if
made at the Closing Date (except to the extent such representation or warranty specifies an earlier
date, in which case such representation or warranty shall be true and correct in all respects as of
such date).

     (b) Performance of Obligations. Each Seller shall have performed in all material
respects all obligations and covenants required to be performed by it under this Agreement and any
other agreement or document entered into in connection herewith prior to the Closing Date (to the
extent such obligations and covenants require performance prior to such time).

     (c) Release of Liens. The Buyer shall have received evidence satisfactory to it from
any Person who held any Encumbrance (other than Permitted Encumbrances) on any of the Purchased
Assets of the release by such Person of such Encumbrance effective upon or concurrent with the
Closing.

     (d) Legal Requirements. No Law shall be in effect which prohibits or materially
restricts the consummation of the Transactions contemplated by this Agreement and the Ancillary
Agreements at the Closing, or which otherwise adversely affects in any material respect the right
or ability of the Buyer to own, operate or control the Purchased Assets, in whole or material part,
and no Action is pending or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-29-

 

threatened by or before a Governmental Authority which, if successful,
could reasonably be expected to result in a Law having such effect or which seeks to obtain from
the Buyer any damages.

     (e) Closing Deliveries. The Sellers shall have delivered to the Buyer all of the
closing documents and agreements set forth in Sections 3.2 and 3.4, and each of
such documents and agreements shall be in full force and effect.

     (f) FIRPTA Compliance. The Sellers shall have delivered to the Buyer the certificate
referred to in Section 6.7(d).

     (g) Termination or Release of Third Party Finders Agreements. The Buyer shall have
received evidence satisfactory to it that all agreements relating to the payment of finder’s fees,
brokerage fees, commissions or similar payments in connection with the Sellers’ entry into this
Agreement or the consummation of the transaction contemplated hereby have been terminated or
released with respect thereto have been granted such that the Buyer will not have any Liability
under such agreements.

     Section 7.2 Conditions Precedent to Sellers’ Obligations. The Sellers’ obligation
to consummate the transactions contemplated hereby shall be subject to the fulfillment of each of
the following additional conditions, any one or more of which may be waived, at the Sellers’ sole
discretion, in writing by the Sellers:

     (a) Representations and Warranties.

          (i) Each of the representations and warranties of the Buyer set forth in this Agreement, or in
any written statement or certificate that shall be delivered to the Sellers by the Buyer under this
Agreement that is not qualified by “Material Adverse Effect” or other materiality qualifications
shall have been true and correct in all material respects as of the date of this Agreement and
shall be true and correct in all material respects as of the Closing Date as if made at the Closing
Date (except to the extent such representation or warranty specifies an earlier date, in which case
such representation or warranty shall be true and correct in all material respects as of such
date); and

          (ii) Each of the representations and warranties of the Buyer set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Sellers by the Buyer under
this Agreement that is qualified by “Material Adverse Effect” or other materiality qualifications
shall have been true and correct in all respects as of the date of this Agreement and shall be true
and correct in all respects as of the Closing Date as if made at the Closing Date (except to the
extent such representation or warranty specifies an earlier date, in which case such representation
or warranty shall be true and correct in all respects as of such date).

     (b) Performance of Obligations. The Buyer shall have performed in all material
respects all obligations and covenants required to be performed by it under this Agreement and any
other agreement or document entered into in connection herewith prior to the Closing Date (to the
extent such obligations and covenants require performance prior to such time).

     (c) Closing Deliveries. The Buyer shall have delivered to the Sellers all of the
closing documents and agreements set forth in Section 3.4.

     (d) Legal Requirements. No Law shall be in effect which prohibits or materially
restricts the consummation of the Transactions contemplated by this Agreement and the Ancillary
Agreements at the Closing, or which otherwise adversely affects in any material respect the right
or ability of the Buyer to own, operate or control the Purchased Assets, in whole or material part,
and no Action is pending or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-30-

 

threatened by or before a Governmental Authority which, if successful,
could reasonably be expected to result in a Law having such effect or which seeks to obtain from
the Buyer any damages.

ARTICLE 8

INDEMNIFICATION

     Section 8.1 Survival of Representations and Warranties.

     (a) All representations and warranties of the Sellers in this Agreement shall survive the
Closing until the 18-month anniversary of the Closing Date (the “Survival Date”);
provided, that:

          (i) the representations and warranties contained in Section 4.2, Section 4.6
and Section 4.7 shall survive until the expiration of the applicable statutes of
limitations relating to such representations and warranties; and

          (ii) any claim for indemnification based upon a breach of any such representation or warranty
and asserted prior to the Survival Date (or, in the case of any representation or warranty
contained in Section 4.2, Section 4.6 and Section 4.7, prior to the
expiration of the applicable statute of limitation relating to such representation or warranty) by
written notice in accordance with Section 8.2 shall survive until final resolution of such
claim.

     (b) The representations and warranties contained in this Agreement (and any right to
indemnification for breach thereof) shall not be affected by any investigation, verification or
examination by any Party hereto or by any Representative of any such Party or by any such Party’s
constructive knowledge (which, for purposes of clarity, excludes actual knowledge) of any facts
with respect to the accuracy or inaccuracy of any such representation or warranty.

     (c) The representations and warranties of the Buyer in Article V of this Agreement
shall terminate upon the Closing. For avoidance of doubt, the covenants of the Buyer shall survive
closing and remain in effect until satisfied or terminated.

     Section 8.2 Indemnification.

     (a) Sellers’ Indemnification Obligations. The Sellers shall, jointly and severally,
indemnify, save and hold harmless the Buyer, its Affiliates and their respective Representatives
from and against any and all costs, losses, Taxes, Liabilities, obligations, damages, lawsuits,
judgments, settlements, awards, deficiencies, claims, demands, expenses (including reasonable costs
of investigation and reasonable attorneys’ fees and expenses), interest, fines, penalties, costs of
mitigation, and other losses actually paid to third parties (herein, “Damages”), incurred
in connection with, arising out of, resulting from or incident to (i) any breach of a
representation or warranty of any Seller contained in this Agreement; (ii) any breach of any
covenant of any Seller contained in this Agreement; or (iii) any Excluded Asset or Excluded
Liability.

          The term “Damages” as used in this Article 8 is not limited to matters asserted by
third parties against the Sellers or the Buyer, but includes Damages incurred or sustained by the
Sellers or the Buyer in the absence of third party claims. Payments by the Buyer of amounts for
which the Buyer is indemnified hereunder, and payments by the Sellers of amounts for which the
Sellers are indemnified hereunder, shall not be a condition precedent to recovery. The Sellers’
obligation to indemnify the Buyer, and the Buyer’s obligation to indemnify the Sellers, shall not
limit any other rights, including without limitation rights of contribution which any Party may
have under statute or common law.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-31-

 

     (b) Buyer’s Indemnification Obligations. The Buyer shall indemnify and save and hold
harmless the Sellers, their respective Affiliates, and their Representatives from and against any
and all Damages incurred in connection with, arising out of, resulting from or incident to (i) any
breach of any representation or warranty made by the Buyer contained in this Agreement; (ii) any
breach of any covenant made by the Buyer contained in this Agreement; or (iii) from and after the
Closing, any Assumed Liability.

     (c) Defense of Claims. If a claim for Damages (a “Claim”) is to be made by a
Party entitled to indemnification (“Indemnified Party”) hereunder against the Party from
whom indemnification is sought (the “Indemnifying Party”), the Party claiming such
indemnification shall, subject to this Section 8.2, give written notice (a “Claim
Notice”) to the Indemnifying Party as soon as practicable after the Party entitled to
indemnification becomes aware of any fact, condition or event which may give rise to Damages for
which indemnification may be sought under this Section 8.3. If any lawsuit or enforcement
action is filed against any Party entitled to the benefit of indemnity hereunder, written notice
thereof shall be given to the Indemnifying Party as promptly as practicable (and in any event
within fifteen (15) calendar days after the service of the citation or summons). The failure of
any Indemnified Party to give timely notice hereunder shall not affect rights to indemnification
hereunder, except to the extent that the Indemnifying Party demonstrates actual damage caused by
such failure. After such notice, if the Indemnifying Party shall acknowledge in writing to the
Indemnified Party that the Indemnifying Party shall be obligated under the terms of its indemnity
hereunder in connection with such lawsuit or action, then the Indemnifying Party shall be entitled,
if it so elects at its own cost, risk and expense, (i) to take control of the defense and
investigation of such lawsuit or action, (ii) to employ and engage attorneys of its own choice to
handle and defend the same unless the named parties to such action or proceeding include both the
Indemnifying Party and the Indemnified Party and the Indemnified Party has been advised in writing
by counsel that there may be one or more legal defenses available to such Indemnified
Party that are different from or additional to those available to the Indemnifying Party, in
which event the Indemnified Party shall be entitled, at the Indemnifying Party’s cost, risk and
expense, to separate counsel of its own choosing, and (iii) to compromise or settle such claim,
which compromise or settlement shall be made only with the written consent of the Indemnified
Party, such consent not to be unreasonably withheld; provided, however, that this
sentence shall not apply to Claims relating to Taxes. If the Indemnifying Party fails to assume
the defense of such claim within fifteen (15) calendar days after receipt of the Claim Notice, the
Indemnified Party against which such claim has been asserted will (upon delivering notice to such
effect to the Indemnifying Party) have the right to undertake, at the Indemnifying Party’s cost and
expense, the defense, compromise or settlement of such claim on behalf of and for the account and
risk of the Indemnifying Party. In the event the Indemnified Party assumes the defense of the
claim, the Indemnified Party will keep the Indemnifying Party reasonably informed of the progress
of any such defense, compromise or settlement. The Indemnifying Party shall be liable for any
settlement of any action effected pursuant to and in accordance with this Section 8.2 and
for any final judgment (subject to any right of appeal), and the Indemnifying Party agrees to
indemnify and hold harmless the Indemnified Party from and against any Damages by reason of such
settlement or judgment.

     (d) Cooperation. The Indemnified Party shall cooperate in all reasonable respects
with the Indemnifying Party and such attorneys in the investigation, trial and defense of such
lawsuit or action and any appeal arising therefrom; provided, however, that the
Indemnified Party may, at its own cost, participate in the investigation, trial and defense of such
lawsuit or action and any appeal arising therefrom. For the avoidance of doubt, nothing contained
in this Section 8.2(d) shall affect the Indemnified Party’s right to employ and engage
separate counsel in accordance with Section 8.2(c)(ii). The Parties shall cooperate with
each other in any notifications to insurers.

     (e) Equitable Relief; No Waiver. Nothing in this Agreement shall (i) limit the right
of any Party to seek specific performance of, or equitable relief with respect to, another Party
with respect to a

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-32-

 

breach of any covenant or agreement set forth in this Agreement or (ii) be deemed
a waiver by any Party to this Agreement of any right or remedy which such Party may have at law or
in equity based on any claim of fraud.

     Section 8.3 Right of Setoff. The Buyer may setoff any amount to which it is
entitled under Section 6.7(e) or this Article 8 against amounts otherwise payable to the
Sellers hereunder, provided that any amount to be setoff is no greater than any amount to which the
Buyer is entitled to under Section 6.7(e) and this Article 8. Neither the exercise nor the
failure to exercise such right of setoff shall constitute an election of remedies or limit the
Buyer in any manner in the enforcement of any other remedies that may be available to it.

ARTICLE 9

MISCELLANEOUS PROVISIONS

     Section 9.1 Confidentiality and Publicity.

     (a) The Mutual Confidentiality and Disclosure Agreement, attached as Exhibit A to the Existing
License Agreement is hereby incorporated in this Agreement as though fully set forth herein. All
terms used in this Section 9.1 and not otherwise defined herein shall have the meanings
assigned to such terms in the Confidentiality Agreement. Subject to this Section 9.1, all
information exchanged between or among the Parties prior to, on and after the date of this
Agreement shall be subject to and treated in accordance with the terms and conditions of the
Confidentiality Agreement. The Parties agree that from and after the Closing Date, the Confidentiality Agreement shall remain in full force
and effect pursuant to its terms with respect to all Confidential Information that does not relate
to the Purchased Assets or the Assumed Liabilities.

     (b) From and after the Closing Date, all Confidential Information primarily concerning the
Purchased Assets and the Assumed Liabilities (the “Buyer Proprietary Information”) shall be
used by the Sellers solely as required to perform their respective obligations, exercise or enforce
their respective rights under this Agreement (or any Ancillary Agreement), or comply with
applicable Law, and for no other purpose. The Sellers shall not disclose, or permit the disclosure
of, any of the Buyer Proprietary Information to any Person except those Persons to whom such
disclosure is necessary to permit the Sellers to perform their respective obligations, exercise or
enforce their respective rights under this Agreement (or any Ancillary Agreement), or comply with
applicable Law. The Sellers shall treat, and will cause their respective Affiliates and the
Representatives and advisors of the Sellers or any of their respective Affiliates to treat, the
Buyer Proprietary Information as confidential, using the same degree of care as the Sellers
normally employ to safeguard its own confidential information from unauthorized use or disclosure,
but in no event less than a reasonable degree of care.

     (c) All Confidential Information obtained by the Buyer (or its Representatives or Affiliates)
from the Sellers (or its Representatives or Affiliates) other than the Buyer Proprietary
Information (the “Sellers’ Proprietary Information”) shall be used by the Buyer solely as
required to perform its obligations, exercise or enforce its rights under this Agreement (or any
Ancillary Agreement), or comply with applicable Law, and for no other purpose. The Buyer shall not
disclose, or permit the disclosure of, any of the Sellers Proprietary Information to any person
except those persons to whom such disclosure is necessary to permit the Buyer to perform its
obligations, exercise or enforce its rights under this Agreement (or any Ancillary Agreement), or
comply with applicable Law. The Buyer shall treat, and will cause its Affiliates and the
Representatives and advisors of the Buyer or any of their respective Affiliates to treat, the
Sellers’ Proprietary Information as confidential, using the same degree of care as the Buyer
normally employ to safeguard its own confidential information from unauthorized use or disclosure,
but in no event less than a reasonable degree of care.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-33-

 

     (d) In the event either Party is requested pursuant to, or required by, applicable Law to
disclose any of the other Party’s Confidential Information (i.e., the Sellers’ Proprietary
Information or the Buyer Proprietary Information, as applicable), it will notify the other Party in
a timely manner so that such Party may seek a protective order or other appropriate remedy or, in
such Party’s sole discretion, waive compliance with the confidentiality provisions of this
Agreement. Each Party will cooperate in all reasonable respects, in connection with any reasonable
actions to be taken for the foregoing purpose. In any event, the Party requested or required to
disclose such Confidential Information may furnish it as requested or required pursuant to
applicable Law (subject to any such protective order or other appropriate remedy) without liability
hereunder, provided that such Party furnishes only that portion of the Confidential
Information which such Party is advised by a reasoned opinion of its counsel is legally required,
and such Party exercises reasonable efforts to obtain reliable assurances that confidential
treatment will be accorded such Confidential Information.

     (e) Except as required by applicable Laws, no Party to this Agreement shall issue any press
release or make any public statement regarding the transactions contemplated hereby without the
prior approval of the other Parties, and the Parties shall issue a mutually acceptable press
release as soon as practicable after the Closing Date. Notwithstanding the foregoing, the Buyer
shall be permitted to make any public statement without obtaining the consent of the Sellers if (i)
the disclosure is required by applicable Laws or the requirements of the SEC or NASDAQ Stock Market
and (ii) the Buyer has first used its reasonable efforts to consult with (but not to obtain the
consent of) the Sellers about the form and substance of such disclosure.

     Section 9.2 Notices. Unless otherwise provided herein, any notice, request,
instruction or other document to be given hereunder by any Party to the other shall be in writing
and delivered in person or by courier, sent by facsimile transmission, sent via overnight delivery
service or mailed by registered or certified mail (such notice to be effective upon receipt), as
follows:

If to the Sellers, addressed to:

Marnac Inc.

9400 N. Central Expressway, Suite 305

Dallas, Texas 75231

Attn: Solomon B. Margolin, M.S., Ph.D.

Telephone: (214) 692-8544

Fax: (214) 692-8510

with a copy to:

Wisener*Nunnally*Gold, LLP

625 West Centerville Road, Suite 110

Garland, Texas 75041

Attn: Robert H. Nunnally, Jr.

Telephone: (972) 840-9080

Fax: (972) 840-6575

If to the Buyer, addressed to:

InterMune, Inc.

3280 Bayshore Boulevard

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-34-

 

Brisbane, CA 94005

Attn: General Counsel

Telephone: (415) 466-2200

Fax: (415) 466-2300

with a copy to:

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Attn: Mark V. Roeder

Telephone: (650) 328-4600

Fax: (650) 463-2600

or to such other place and with such other copies as any Party may designate as to itself by
written notice to the other Parties.

     Section 9.3 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California without regard to the conflicts of laws principles thereof that would require the
application of the laws of any other jurisdiction.

     Section 9.4 Representation By Counsel. Each Party hereto represents and agrees
with each other that it has been represented by or had the opportunity to be represented by,
independent counsel of its own choosing, and that it has had the full right and opportunity to
consult with its respective attorney(s), that to the extent, if any, that it desired, it availed
itself of this right and opportunity, that it or its authorized officers (as the case may be) have
carefully read and fully understand this Agreement in its entirety and have had it fully explained
to them by such Party’s respective counsel, that each is fully aware of the contents thereof and
its meaning, intent and legal effect, and that it or its authorized officer (as the case may be) is
competent to execute this Agreement and has executed this Agreement free from coercion, duress or
undue influence.

     Section 9.5 Expenses. Except as expressly provided for herein, all expenses,
including the fees of any attorneys, accountants, investment bankers, brokers, finders or others
engaged by a Party, incurred in connection with this Agreement, the Ancillary Agreements and the
transactions contemplated hereby and thereby, shall be paid by the Party incurring such expenses.

     Section 9.6 Entire Agreement. This Agreement (including the documents and the
instruments referred to herein) and the Confidentiality Agreement constitute the entire agreement
among the Parties pertaining to the subject matter hereof and supersede all prior agreements,
understandings, negotiations and discussions, whether written and oral, among the Parties.

     Section 9.7 Amendment; Waiver. This Agreement may not be amended except in an
instrument in writing signed on behalf of each of the Parties hereto. No amendment, supplement,
modification or waiver of this Agreement shall be binding unless executed in writing by the Party
to be bound hereby. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver
constitute a continuing waiver unless otherwise expressly provided.

     Section 9.8 Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced as a result of any rule of law or public policy,
all other terms and other provisions of this Agreement shall nevertheless remain in full force and
effect so long as the economic or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-35-

 

legal substance of the transactions contemplated by this
Agreement is not affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the Parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the Parties as closely as possible in an acceptable manner to the end that the transactions
contemplated by this Agreement are fulfilled to the greatest extent possible.

     Section 9.9 Assignment. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be
assigned by any of the Parties hereto (whether by operation of law or otherwise) without the prior
written consent of the other Parties hereto; provided, however, that such written
consent will not be required by an assignment by the Buyer (a) to any of its Affiliates (in which
case the Buyer shall remain liable for all obligations of the Buyer hereunder, including the
performance or nonperformance of any actions or omissions of its Affiliates) or (b) in connection
with a merger, sale or transfer involving all or substantially all of the assets of the Buyer.
Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and
be enforceable by the Parties and their respective permitted successors and assigns.

     Section 9.10 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which shall constitute
one and the same agreement. Each of the Parties agrees to accept and be bound by facsimile
signatures hereto.

     Section 9.11 Waiver of Jury Trial. Each signatory to this Agreement hereby waives
its respective right to a jury trial of any permitted claim or cause of action arising out of this
Agreement, any of the transactions contemplated hereby, or any dealings between any of the
signatories hereto relating to the subject matter of this Agreement or any of the transactions
contemplated hereby. The scope of this waiver is intended to be all encompassing of any and all
disputes that may be filed in any court and that relate to the subject matter of this agreement or
any of the transactions contemplated hereby, including, without limitation, contract claims, tort
claims, and all other common law and statutory claims. This waiver is irrevocable, meaning that it
may not be modified either orally or in writing, and this waiver shall apply to any subsequent
amendments, supplements or other modifications to this agreement, any of the transactions
contemplated hereby or to any other document or agreement relating to the transactions contemplated
hereby.

     Section 9.12 Consent to Jurisdiction. EACH PARTY HERETO IRREVOCABLY AND
UNCONDITIONALLY (I) AGREES THAT ANY SUIT, ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF THIS
AGREEMENT MAY BE BROUGHT IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF
CALIFORNIA OR, IF SUCH COURT DOES NOT HAVE JURISDICTION OR WILL NOT ACCEPT JURISDICTION, IN ANY
COURT OF GENERAL JURISDICTION IN THE COUNTY OF SAN FRANCISCO, CALIFORNIA; (II) CONSENTS TO THE
JURISDICTION OF ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING; AND (III) WAIVES ANY
OBJECTION WHICH SUCH PARTY MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING
IN ANY SUCH COURT.

     Section 9.13 Attorney Fees. If any Party to this Agreement brings an Action to
enforce its rights under this Agreement in accordance with the provisions hereof, the prevailing
Party shall be entitled to recover its actual out-of-pocket costs and expenses, including without
limitation reasonable attorneys’ fees reasonably incurred in connection with such Action, including
any appeal of such Action.

     Section 9.14 Remedies Cumulative; Specific Performance. The rights and remedies of
the Parties hereto shall be cumulative (and not alternative). The Parties agree that, in the event
of any breach or threatened breach by any Party of any covenant, obligation or
other provision set forth in this

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-36-

 

Agreement for the benefit of any other Party, such other Party
shall be entitled (in addition to any other remedy that may be available to it) to (a) a decree or
order of specific performance or mandamus to enforce the observance and performance of such
covenant, obligation or other provision, and (b) an injunction restraining such breach or
threatened breach.

     Section 9.15 Time is of Essence. Time is of the essence with respect to the
performance of this Agreement.

     Section 9.16 Executory Nature of the Duties Imposed by this Agreement. This
Agreement is intended to require the Sellers and the Buyer to perform a number of executory duties
throughout the term of this Agreement. The Parties intend that this Agreement shall be governed by
Section 365 of the Bankruptcy Code.

     Section 9.17 Bankruptcy Rights. In the event this Agreement is terminated or
rejected by either the Buyer or any Seller or the Buyer’s or any Seller’s trustee or debtor in
possession in bankruptcy (or receiver) under applicable bankruptcy or receivership laws due to the
Buyer or such Seller’s bankruptcy or receivership, then all rights and licenses granted by the
Sellers to the Buyer and by the Buyer to the Sellers shall be deemed to be, for purposes of Section
365(n) of the Bankruptcy Code and any other similar law or regulation in any other country,
licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy
Code. The parties intend such rights and licenses to be subject to the protections afforded the
non-terminating party under Section 365(n) of the Bankruptcy Code or any similar law or regulation
in any other country.

     Section 9.18 Release. Each Party hereby releases the other Party, its
successors and assigns, and their respective Representatives, in each case from and against any and
all grievances, rights, actions, causes of action, claims, demands, complaints, obligations,
liabilities or controversies of any and all kinds, nature and character whatsoever, legal and
equitable, whether known or unknown, foreseen or unforeseen, that a Party has or shall or may have
under any Law, arising out of, related to, or in connection with the Existing License Agreements
(the “Released Claims”). EACH PARTY HEREBY EXPRESSLY WAIVES THE BENEFIT OF ANY STATUTE OR
RULE OF LAW THAT, IF APPLIED TO THIS AGREEMENT, WOULD OTHERWISE EXCLUDE FROM ITS BINDING EFFECT ANY
RELEASED CLAIMS NOT KNOWN BY SUCH PARTY TO EXIST WHICH AROSE PRIOR TO THE SIGNING OF THIS
AGREEMENT. Each Party understands and acknowledges that it may not currently know of losses or
claims or may have underestimated the severity of losses. Part of the consideration provided by
this Agreement was given in exchange for the release of such claims. Each Party hereby waives any
rights or benefits under California Civil Code Section 1542 (or any similar statute in any other
jurisdiction), which provides that: “A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at the time of executing the release, which
if known by him must have materially affected his settlement with debtor.”

     Per the Interim Agreement, the Parties have previously acknowledged that there has been a
dispute surrounding the interpretation of Paragraph 5.2(a) of the Existing License Agreement and
whether payment is due and owing by the Buyer thereunder. However, as a result of this Agreement
and the transactions contemplated herein, the Parties acknowledge and agree that such dispute has
been resolved and no payment under that Paragraph 5.2(a) of the Existing License Agreement is due
and owing by the Buyer to the Sellers.

[SIGNATURE PAGE FOLLOWS]

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-37-

 

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the
date first above written.

	 	 	 	 	 
	 	BUYER

INTERMUNE, INC.

 	 
	 	/s/ Daniel G. Welch
 	 
	 	By: Daniel G. Welch 	 
	 	Its: President and CEO 	 
	 
	 	SELLERS

MARNAC, INC.

 	 
	 	/s/ Solomon B. Margolin
 	 
	 	By: Solomon B. Margolin 	 
	 	Its: President 	 
	 
	 	 	 
	 	                                                      /s/ Solomon B. Margolin
 	 
	 	DR. SOLOMON B. MARGOLIN 	 
	 	 	 
	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]